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 Manipulating Somatic Cells to Remove Barriers  
in Induced Pluripotent Stem Cell Reprogramming 
 
Abstract 
 
Development leads unidirectionally towards a more restricted cell fate that is 
usually stable. However, it has been proven that developmental systems are reversible 
by the success of animal cloning of a differentiated somatic genome through somatic cell 
nuclear transfer (SCNT). Recently, reprogramming of somatic cells to a pluripotent 
embryonic stem cell (ESC)-like state by introducing defined transcripton factor has been 
achieved, resulting in the generation of induced pluripotent stem cells (iPSCs), which 
resemble ESCs. iPSC reprogramming is of great medical interest, as it has the potential 
to generate a source of patient-specific cells. However, the dangerous delivery method, 
low efficiency, and slow kinetics of the reprogramming process have hampered progress 
with this technology. 
To tackle these blockades of reprogramming and generate clinically useful iPSCs, 
we have modulated normal developmental signal transduction pathways of keratinocytes, 
namely Notch signaling using a chemical. Notch inhibition by a chemical inhibitor, 
DAPT, improves the efficiency of reprogramming keratinocytes to pluripotency. 
Inhibition of Notch replaces two of the four exogenous reprogramming factors, 
oncogene Klf4 and cMyc. Importantly, pharmacological inhibition of Notch provides an iv 
 
escape from suppression of p53 activity, which is required to enhance reprogramming 
without Klf4 and cMyc and possibly leads to genetic mutations.  
In another approach to improve the efficiency and kinetics of reprogramming, we 
have generated an allelic series of DNA methyltransferase1 (Dnmt1) mouse embryonic 
fibroblasts (MEFs) and reprogrammed them with four reprogramming factors. A cell 
line that has 90% reduced Dnmt1 levels decreases the methylation levels of Oct4 
regulatory regions. Significantly, the hypomorphic Dnmt1 cell line enhances the 
efficiency and dynamics of reprogramming by directly activating Oct4 and bypassing 
the intermediate states. 
Ultimately, the knowledge gained from experimental manipulation of cell fates 
and epigenetic barriers in iPSC reprogramming will contribute to a better understanding 
of the reprogramming technology and its controlled mechanism to achieve pluripotency. 
Furthermore, our study hopes to facilitate the development of clinical applications to 
personalized regenerative medicine.  
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Chapter 1  
 
The Progress of Induced Pluripotent Stem Cell Reprogramming 
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Abstract  
 
Ground-breaking advances in nuclear reprogramming have been made by 
reversing the normal development using defined factors. A small set of transcription 
factors (Sox2, Oct4, Klf4 and c-Myc) directly confer embryonic stem cell (ESC)-like 
characteristics to somatic fibroblasts. The resulting induced pluripotent stem cells 
(iPSCs) are self-renewing and pluripotent. However, the low efficiency and viral 
delivery of transgenes provide a significant handicap for clinical applications as well as 
mechanistic studies. Therefore, many research groups have proposed various approaches 
to tackle the technical limitations and understand the systemic challenges to induce 
pluripotency. Moreover, iPSCs can teach us about principles of normal development and 
disease, which may ultimately apply to patients for custom-made cell therapy. 
 
 
 
 
 
 
 
 
 
  
 
3 
 
Introduction  
Animal development starts as the fertilized egg undergoing a programmed 
process of cell proliferation and differentiation that generates the wide variety of cell 
types which an individual is composed of. Decades of research in cell fate changes 
during development have led to the view that this differentiation process, in vivo, is 
irreversible, and differentiated cells are committed to their cell fate. However, 
pioneering studies from somatic cell reprogramming with Xenopus levies (Gurdon et al., 
1958) to the cloning of Dolly the sheep proved that fully differentiated somatic cell 
nuclei can be reprogrammed back to an embryonic-like state by factors present in 
oocytes (Wilmut et al., 1997). The recent breakthrough made by Yamanaka and 
colleagues revealed that differentiated somatic cells can reverse back to a pluripotent 
state in vitro by the introduction of a defined combination of transcription factors that 
are highly enriched in embryonic stem cells (ESCs) (Takahashi and Yamanaka, 2006).  
The beauty of this powerful technique, transcription-factor-induced 
reprogramming to ESC-like states, lies in its simplicity and robustness. Many different 
cell types from the wide range of species including human can also be reprogrammed to 
pluripotency by ectopic over-expression of certain factors, raising the possibility of the 
clinical application of personalized stem cell-based therapies without immune rejection 
or ethical concerns as well as studying genetic diseases in vitro. 
 This opening chapter focuses on the development of pluripotency 
reprogramming technology and various approaches to overcome its limitations to 
produce safer and applicable stem cells that could directly differentiate into target cell  
 
4 
 
types for cell replacement therapies. The following body of work clearly demonstrates 
the possibility of manipulating cell fate to pluripotency by new ways and of lowering the 
epigenetic barrier to achieve pluripotency. 
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State of the Art Technology in Stem Cells 
The Pluripotent Stem Cell  
The years since Takahashi and Yamanaka‘s breakthrough have seen the term 
pluripotency assigned to a variety of cell types with a wide range of functional capacities. 
To understand their discovery, we first need to define what it means to be pluripotent.  
The term pluripotency describes a cell that has the ability to differentiate into cell 
derivatives of all three primary embryonic germ layers: the ectoderm, mesoderm, and 
endoderm. More stringently, it describes a cell that can give rise to an entire organism, 
generating every cell type in the organism. The property of cell pluripotency was first 
discovered, when two cells of an early sea urchin blastocyst that were separated 
generated two complete sea urchins (Driesch, 1891). Many decades later, research of 
embryo aggregation and blastocyst chimaerism in the 1960s and 1970s solidified the 
idea that the cells of the inner cell mass (ICM) of the mouse blastocyst were pluripotent 
(Brinster, 1974; Dewey et al., 1977; Gardner, 1968). 
This powerful developmental potency, pluripotency, which gives rise to form 
any cell type of interest, brings attention to the usefulness in a clinical and scientific 
standpoint. For this purpose, an ideal cell type, embryonic stem cells (ESCs) were 
derived in vitro from the ICM of the pre-implantation embryo, possessing the ability to 
self-renew and the capacity to generate definitive ectoderm, mesoderm, and endoderm-
derived lineages. The first derivation of ESCs was performed from mouse blastocystes 
in 1981 (Evans and Kaufman, 1981; Martin, 1981), leading to the era of culturing  
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pluripotent stem cells in a dish. Then the first successful human ESCs derivation was 
followed in 1998 (Thomson et al., 1998), opening a door to the idea of cell therapy.  
Due to the pluripotent and self-renewing nature of ESCs, there has been an 
interest to convert adult somatic cells into ESCs, named nuclear reprogramming. The 
oldest reprogramming method is somatic cell nuclear transfer (SCNT)-the genetic 
material from the donor cell being reprogrammed is transferred to an enucleated oocyte 
from the recipient that has reprogramming activity, resulting in the development of a 
new organism (Gurdon and Byrne, 2003). To generate patient-specific ESCs, there have 
been considerable efforts to clone blastocystes from patient somatic cells by SCNT. 
However, SCNT carries not only ethical concerns regarding the destruction of human 
embryos, but also the shortage of donated eggs for the use of recipient cells in nuclear 
transfer. Moreover, due to technical difficulties, it is a challenge to achieve successful 
SCNT in human (Egli et al., 2011a). 
Next, another nuclear reprogramming method, called cell fusion, had been 
executed by fusing pluripotent ESCs and differentiated cells, generating a pluripotent 
heterokeryon. Tada and colleagues established the ES-thymocyte hybrid cells by fusing 
adult thymocytes with ESCs, which contribute to all three primary germ layers of 
chimeric embryos (Tada et al., 2001). Likewise, Eggan and collegues produced human 
somatic hybrid cells by fusing human BJ fibroblasts with a human ESC line (Cowan et 
al., 2005). The resulting cells have morphology, marker expression patterns, and 
differentiation potential characteristic of human ESCs. Although cell fusion is useful for  
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studying reprogramming, it has a limitation in therapies due to the tetraploid DNA 
content of the hybrids. 
 
Induced Pluripotent Stem Cells (iPSCs) 
Despite many hindrances to derive human ESCs, researchers have explored the 
pathways which derive pluripotency and regulate the maintenance of ESCs. In 2006 
Takahashi and Yamanaka developed a groundbreaking technology in the field of nuclear 
reprogramming. They found that differentiated somatic cells can be reprogrammed to a 
pluripotent state by a set of defined factors (Takahashi and Yamanaka, 2006). The 
resulting cells are named induced pluripotent stem cells (iPSCs), which could be an 
alternative source of personalized patient-specific stem cells. 
Previously, there have been reports of factor-mediated cell conversion from one 
cell type to another within closely related lineages that share developmental history. 
Discovering a key component such as a specific transcription factor or environmental 
products that distinguish different cell types within the same lineage during 
differentiation allowed cell conversion from fibroblasts to myoblasts in the mesodermal 
lineage (Davis et al, 1987), from B cells to macrophages within the ectodermal origin or 
the hematopoietic system (Kulessa et al., 1995; Nerlov and Graf, 1998; Xie et al., 2004), 
or from pancreatic cells to liver cells between the endodermal lineages. In 
developmental perspective, Takahashi and Yamanaka's finding is a historic contribution 
because reprogramming somatic cells to pluripotency is a complete reversal of normal 
developmental processes just by a few defined factors. Interestingly, Takahashi and  
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Yamanaka‘s finding provides a lesson that differentiated cells can be genetically 
engineered to achieve pluripotency rather than the necessity of the complex 
environmental factors such as the cytoplasm of an egg or an ESC.  
By screening 24 candidate genes selected for their links to ESC pluripotency, 
they found four reprogramming factors—Oct4, Sox2, Klf4, and cMyc—that are 
sufficient to directly confer ESC characteristics to somatic fibroblasts (Takahashi and 
Yamanaka, 2006 and 2007). They reprogrammed mouse embryonic fibroblasts (MEFs) 
and adult fibroblasts to pluripotent ES-like cells by over-expressing, by retrovirus-
mediated transduction, four transcription factors followed by selection for activation of 
the Oct4 target gene, first-generation F-box containing protein 15 (Fbx15). Rarely 
observed ES-like colonies that had activated Fbx15 were called iPSCs. 
These Fbx15-positive iPSCs demonstrated pluripotency by their ability to form 
teratoma. However, they failed to contribute to adult chimeras. Although this pluripotent 
state depended on the viral over-expression of Oct4 and Sox2 genes, the core ESC factor, 
such as endogenous Oct4 and Nanog genes were either not expressed or expressed at a 
lower level than in ESCs. Also, they showed incomplete demethylation of the promoters 
of Oct4 and Nanog. Therefore, the Fbx15-activated iPSCs did not correspond to ESCs, 
implying that they represented an incomplete state of reprogramming. By using the Oct4 
or Nanog selection method, which is a more stringent selection criterion for pluripotnecy, 
the Oct4 or Nanog-activated iPSCs were fully reprogrammed iPSCs. Their global gene 
expression profiles were indistinguishable from those of ESCs. In contrast to the Fbx15-
iPSCs, they were hypomethylated in endogenous Oct4 and Nanog promoters. Also, they  
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generated the wide range of tissues in a chimera and contributed to the germ line 
(Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007). Importantly, they 
generated last gestation embryos through tetraploid complementation, the most stringent 
test for developmental potentcy (Wernig et al, 2007). Therefore, these iPSCs exhibited 
all the molecular and functional characterstics of ESCs, indicating that Oct4 and Nanog 
positive iPSCs were indistinguishable from ESCs. 
In 2007, Yamanaka and Thomson‘s group independently announced the 
successful derivation of iPSC from human fibroblasts (Takahashi et al., 2007; Yu et al., 
2007). The resulting human iPSCs closely resemble human ESCs in their morphology, 
gene expression and the epigenetic status of pluripotency genes, and can differentiate 
into the cells of the three germ layers in vitro and in vivo. The derivation of human 
iPSCs holds enormous potential for regenerative medicine.  
 
Technical Limitations of iPSC Reprogramming 
Although iPSC technology is a promising resource in regenerative medicine, the 
clinical utility of this technique is compromised by two main problems. First is the 
delivery method to generate iPSCs; the retrovirus-mediated transgenes tend to induce 
malignant transformation. Mice derived from iPSCs frequenctly developed cancer 
(Okita et al., 2007). Secondly, the efficiency of reprogramming is extremely low 
(~0.001-1%) (Takahashi and Yamanaka, 2006).  
In addition to considering the induction of malignant transformation by the 
retroviral delivery of the reprogramming factors, it was questioned whether insertional  
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mutagenesis could potentially be required for iPSC reprogramming. Previous reports 
have shown that replication-defective retroviral integrations themselves were able to 
activate endogenous genes to promote survival in hematopoietic stem cells in vitro 
(Kustikova et al. 2005). Similarly, we have to contemplate the possibility that one or 
several copies of the virus in iPSCs might integrate into and activate a gene that triggers 
the acquisition of a pluripotent state. When iPSCs were derived from fibroblasts using 
retroviruses, they carried ~10- 20 proviral transgenes that expressed Oct4, Sox2, Klf4 
and cMyc, which were found at different copy numbers per clone (Maherali et al., 2007; 
Takahashi and Yamanaka, 2006; Wernig et al., 2007). In 2008, Yamanaka and 
colleagues generated iPSCs from lineage-committed differentiated epithelia cells, 
primary hepatocytes (liver cells) and gastric epithelia cells (stomach cells) using the 
same reporter and the selection system they used in the first generation of the fibroblast-
derived iPSCs (Aoi et al., 2008). They showed that iPSCs derived from hepatocytes and 
stomach cells had fewer viral integration sites than those in fibroblast-derived iPSCs. In 
addition, the sequencing result of viral insertion sites in iPSCs derived from fibroblasts, 
stomach cells, and liver cells did not show any common integration sites, suggesting that 
insertional mutagenesis does not contribute to the induction of pluripotency (Aoi et al., 
2008; Varas et al., 2008). Therefore, the transgenic methods of iPSC generation that 
could potentially cause cancer needed to be improved. 
It is conceivable that the frequency at which a single somatic cell gets infected 
by the four viral transgenes at the same time in the appropriate stoichiometry is 
extremely low, resulting in the low overall efficiency of reprogramming. To address the  
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question of whether viral infection is indeed the rate-limiting step, several groups have 
generated a ‗secondary system,‘ in which cells can reactivate all four factors at the 
correct stoichiometry by using a doxycycline-inducible system, assuming that it should 
give rise to iPS cells at an efficiency close to 100% based on the theory that nearly100% 
of the four reprogramming factors can be reactivated (Hockemeyer et al., 2008; 
Maherali et al., 2008; Wernig et al., 2008a). When secondary mouse or human 
fibroblasts are treated with doxycycline, 3-5% of the cells gave rise to iPSCs, that is, a 
30- to 100-fold increase in efficiency compared to primary fibroblasts infected directly 
with viruses, indicating that viral infection and expression can affect the efficiency of 
reprogramming. However, the frequency of iPSC generation is still unexpectedly low, 
suggesting that the expression of the four factors alone is insufficient in itself to 
reprogram somatic cells to pluripotency and that there is a roadblock such as epigenetic 
barriers that must affect the overall efficiency of reprogramming. 
 
 
Tackling Obstacles of iPSC Reprogramming  
Toward Transgene-free iPSC Reprogramming  
A variety of technologies have been developed to generate transgene-free iPSCs 
for clinical practice. iPSCs are initially produced by using retroviral or lentiviral 
transduction of transcription factors, and these transgenes are randomly inserted into the 
host genome, holding a risk of tumorgenicity. In fact, chimeras made with iPSCs 
harboring the most potent proto-oncogene cMyc have a high incident of tumor formation  
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due to the reactivation of the cMyc transgene expression (Okita et al., 2007). First, in an 
effort to reduce this risk, it has been shown that iPSCs can be derived in the absence of 
the cMyc, albeit with a low efficiency of reprogramming (Nakagawa et al., 2008; 
Wernig et al., 2008).  
Several alternative methods for delivering these reprogramming factors other 
than through retrovirus or lentivirus have been developed, so called non-integrative or 
excisable virus approaches for iPSC derivation. Researchers have established iPSCs by 
using adenovirus or transient plasmids, which are non-integrating (Okita et al., 2008; 
Stadtfeld et al., 2008b), and transposon or loxP-flanked lentiviral, which are removable 
(Somers et al., 2010; Woltjec et al., 2009). Moreover, mouse and human iPSCs could be 
generated by the direct delivery of recombinant reprogramming protein (Kim et al., 
2009a; Zhou et al., 2009). The overall efficiency of these reprogramming technologies 
was one or two magnitudes lower than the rates of retrovirus or lentivirus methods. Thus, 
the original retrovirus delivery method for the generation of iPSCs has been improved 
by avoiding viral insertions into the iPSCs genome, however, all of these trials still 
could not overcome the low efficiency of reprogramming. 
Due to the low frequency of producing iPSCs with these transient expression 
methods, researches have been directed toward increasing the efficiency by seeking 
further optimizations for future research or therapeutics. Many efforts have been made to 
improve the reprogramming efficiency as well as avoid transgene integration risk by 
searching for chemicals or signaling pathways that may govern the mechanism of 
reprogramming. Chromatin modifiers, various growth factors, and many other chemical  
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compounds have been reported which could not only improve the efficiency of 
reprogramming but also be used for reprogramming transgene substitutes. Histone 
deacetylase inhibitors, for example, valproic acid (VPA) improves the reprogramming 
efficiency by more than 100-fold and also allows reprogramming without cMyc in 
fibroblasts (Hungfu et al., 2008a). Following studies have shown that VPA enabled 
reprogramming human fibroblasts into iPSCs with only two factors, Oct4 and Sox2 
(Hungfu et al., 2008b). Histone methyltransferase inhibitor, BIX-01294, significantly 
increases the efficiency of reprogramming and can substitute for Sox2 in MEFs (Shi et 
al., 2008a and 2008b). In addition, small molecule inhibitors that control signaling 
pathways, such as Wnt 3A, ALK5 inhibitors, and Tgf- β inhibitors have also been found 
to improve the induction of iPSC generation and replace reprogramming factors (Hungfu 
et al., 2008a; Ichida et al., 2009; Maherali et al. 2009; Shi et al., 2008b). For example, 
RepSox, which is a functional target of Tgf-β type I receptors, specifically ALK4/5 as 
well as ALK2, is an efficient small molecule replacement of Sox2 and cMyc and 
facilitates iPSC reprogramming (Ichida et al., 2009). Vitamin C treatment or exposure to 
a hypoxic environment has also found to enhance the generation of iPSCs (Esteban et al., 
2010).  
Along with chemical approaches, the tumor suppressor protein p53 and cell cycle 
regulator INK4A have been reported to act as a barrier to the reprogramming of somatic 
cells to iPSCs. The repression of these genes removes cell-cycle control checkpoints, 
thereby increasing reprogramming efficiency (Kawamura et al., 2009; Marión et al., 
2009; Li et al., 2009; Utikal et al.,2009). The combination of p53siRNA and a  
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transcription factor, UTF1, with the reprogramming factors increase the efficiency of 
iPSC generation from human embryonic fibroblasts more than 100-fold (Zhao et al., 
2008). Another transcription factor, ESRRB, has also been found to enhance the 
reprogramming efficiency and replace Klf4 (Feng et al., 2009). However, none of these 
chemical compounds, growth factors, or signaling control can generate transgene-free 
iPSCs. 
Recently, iPSCs have been generated from mouse and human somatic cells by 
using direct transfections of mature microRNAs (miRNA) (Miyoshi et al., 2011), which 
are well-characterized regulators of development and differentiation (Lee et al., 1993; 
Ruvkun, 2001). The miRNAs techniques have benefits from the perspective of potential 
clinical translation due to the fact that this reprogramming method does not require 
vector-based gene transfer. It also shows efficient and faster reprogramming kinetics 
than retroviral or lentiviral vectors, however it does operate at considerably lower 
efficiency. 
More recently, iPSC were derived from fibroblasts using modified RNA 
encoding the iPS reprogramming factors, resulting in transgene-free iPSCs at higher 
efficiency (Mandal et al., 2013; Warren et al., 2010). The mRNAs were synthesized by 
using in vitro transcription reactions and delivered into the cytoplasm by endocytosis. In 
light of their study, they overcome cytotoxicity upon exogenous RNA transfection by 
modifying mRNAs, which are synthesized with the complete substitution of uridine and 
cytidine with the modified ribonucleotides pseudouridine and 5-methylcytidine, thereby 
allowing robust and sustained protein expressions of iPS factors. Modified mRNA  
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technology raises hope for cell-based therapeutic applications by large-scale production 
of transgene-free, patient specific iPSCs. However, it still retains some disadvantages. It 
is costly, labor intensive, and technically challenging, since this method requires a 
repeated administration of modified RNAs due to its labile nature and relatively short 
half-life. Also, it shows relatively slow kinetics. Thus, it will require further 
optimization to be useful in research or for future therapeutic purpose. 
  
Starting with Various Somatic Cell Types  
iPS technology has made major progress towards a transgene-free 
reprogramming, nevertheless the cell origins and molecular mechanisms of iPSC 
induction remain elusive. The low efficiency of the iPSC derivation has been argued to 
depend on the presence of rare stem cells within the starting population, because the 
frequency of the adult stem cells‘ existence in many tissues is about the same as the 
success rate of iPSC reprogramming. The Jaenisch group first attempted to reprogram 
terminally differentiated mature B lymphocytes to pluripotency to evaluate whether 
terminally differentiated cells can give rise to iPSCs (Hanna et al., 2008). B cells carry 
differentiation-associated DNA rearrangements, which serve as unequivocal genetic 
markers of their differentiation state (Hochedlinger and Jaenisch, 2002). The ectopic 
expression of Oct4, Sox2, Klf4 and cMyc alone was not sufficient to reprogram B 
lymphocytes into iPSCs, even applying to ‗secondary‘ systems (Wernig et al., 2008a), 
however, terminally differentiated adult cells could reprogram to iPSCs by either 
additional over-expression of the transcription factor Cebpα or knockdown of the  
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transcription factor Pax5, which maintained B cell identity (Hanna et al., 2008). The 
Hochedlinger group also proved that terminally differentiated pancreatic β cells that 
were genetically marked could be reprogrammed to iPSCs by four reprogramming 
factors, although with a low frequency (Stadtfeld et al., 2008a). These results 
demonstrated that adult stem cells were unlikely to be the selective cell type in 
successful reprogramming experiments.  
Many groups then started to reprogram with a wide variety of differentiated cell 
types such as neural progenitors, melanocytes, and keratinocytes with an idea that 
different cell biology—gene expression profile, epigenetic status, developmental 
potential etc. —may significantly contribute to increasing reprogramming efficiency and 
possibly reducing iPSC factors. It is possible different somatic cell types have different 
endogenous gene expression profiles that may aid in their reprogramming. From the 
previous reports that iPSCs derived from fibroblasts using retroviruses have different 
copy numbers of each of the four factors, we can predict that precise relative amounts of 
the individual transcription factors are important for reprogramming (Maherali et al., 
2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007). This is consistent with 
observations that Oct4 and Sox2 levels in ESCs are critical for maintaining a self-
renewing pluripotent state (Kopp et al., 2008; Niwa et al., 2000). Therefore, if each of 
different cell types expresses certain amounts of endogenous iPS genes or other 
pluripotency related genes, these levels of expressions in the particular cell type may 
allow the cell to achieve pluripotency without certain iPSC factor and/or facilitate 
reprogramming efficiency.  
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In addition, when iPSCs were derived from hepatocytes and stomach cells, the 
viral infectivity of these different cell types was different from those of fibroblasts. 
iPSCs were obtained with a lower efficiency of retrovial transduction (30 to 45%), 
although they could not be generated from MEFs at the same infection ratio (Aoi et al., 
2008). This indicates that different cell types other than fibroblasts could increase the 
efficiency of reprogramming, due to a higher acceptance of viral transduction.  
With respect to iPS factor reduction, one of the major advances has shown that 
neural stem cells (NSCs) transduced with only Oct4 can be reprogrammed into iPSCs 
(Kim et al., 2009). Consistent with the notion that, the number of reprogramming factors 
can be reduced when certain somatic cell type endogenously expresses appropriate 
levels of complementing factors to induce pluripotency, NSCs express higher levels of 
endogenous Sox2, cMyc, and Klf4 than those of ESCs, which makes them reprogram to 
iPSCs in the absence of these three reprogramming factors. When transduced with two 
factors, NSCs can dramatically increase the reprogramming efficiency; mouse NSCs can 
give rise to iPSCs up to 50 times more efficiently than mouse fibroblasts (Kim et al., 
2008). In addition to the high expression levels of Sox2, cMyc, and Klf4, NSCs 
endogenously express several other pluripotency markers, such as SSEA-1. This may 
possibly make them reprogram faster and more efficient than MEFs. However, NSCs are 
an undesirable cell type due to their difficult accessibility, when considering future 
clinical application of iPSCs. 
Several groups have evaluated whether melanocytes or keratinocytes from 
ectodermal origin which are easily accessible from patient‘s skin are also able to be  
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reprogrammed into iPSCs. Melanotyes did not require ectopic Sox2 expression for the 
conversion into iPSCs due to their endogenous program and gave rise to iPSCs at three 
times higher efficiencies than fibroblasts (Utikal et al., 2009b). Moreover, by four iPS 
factor reprogramming, human keratinocytes underwent reprogramming at least 100- fold 
more efficient and two-fold faster than human fibroblasts (Aasen et al., 2008; Maherali 
et al., 2008) Keratinocytes can also be reprogrammed only with three factors (OCT4, 
SOX2, KLF4) due to their higher expression level of CMYC than that of fibroblasts 
(Aasen et al., 2008).  
A pluripotent stem cell state has now been induced in a plethora of differentiated 
cell types: from mouse to human fibroblasts, and then to a wide variety of other cell 
types, including pancreatic β-cells, NSCs, mature B cells, stomach cells, liver cells, 
melanocytes, adipose stem cells, and keratinocytes, demonstrating the seemingly 
universal capacity to alter their cellular identity to iPSCs. However, the frequencies of 
converting these various cell types to a pluripotent state and the possibility of iPS factor 
replacements by the endogenous genetic profile vary, suggesting that the cell type 
selection affects efficient iPSC generation. Thus, the best combination of the right cell 
type to facilitate reprogramming and transgene-free methods can bring iPSC technology 
realistically closer to clinical application.  
However, there still remained several unsolved questions. One of the main 
questions that needed to be investigated is the identity and property of the starting cells 
that give rise to iPSCs. NSCs were less differentiated progenitor states. Keratinocyte 
cultures contained more progenitors than in fibroblast cultures. It is possible that less  
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differentiated somatic cells can be reprogrammed more efficiently than more or 
terminally differentiated cells. Alternatively, keratinocytes have a transcriptional state 
(Dotto, 2008), which could be more amenable to reprogramming than fibroblasts. It will 
undoubtedly be interesting to investigate the question of whether the less differentiated 
state of a cell or certain cell property, such as self-renewing capacity, can affect its 
reprogramming efficiency into iPSCs.  
 
 
Overcoming Epigenetic Barriers 
Epigenetic Barriers 
In 1957, Conrad Waddington proposed the concept of an epigenetic landscape, 
which represented the cellular decision-making process during development 
(Waddington, 1957). Epigenetics is a phenomenon that changes the final outcome of a 
locus or chromosome, resulting in establishing and maintaining stable cellular 
phenotypes, without changing the DNA sequence. For example, cellular differentiation 
could be considered an epigenetic phenomenon, because it generates diverse cell types 
with disparate gene expression profiles and distinct cellular functions, while sharing an 
identical genotype in a multicellular organism. During differentiation, cells achieve their 
own lineage by adopting distinct states that are highly resistant to perturbation. An 
important mechanism for lineage restriction involves epigenetic changes that are 
nonetheless stable and heritable (Goldberg, 2007).   
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The best characterized epigenetic machinery is DNA methylation, which is a 
stable and heritable mark involved in many biological processes, including gene 
regulation, X-chromosome inactivation, and genomic imprinting. It occurs on cytosine 
residues of CpG dinucleotides and correlates with transcriptional repression (Goll and 
Bestor, 2005). Tissue-specific patterns of DNA methylation are established by de novo 
DNA methyltransferase Dnmt3a and Dnmt3b and followed by Dnmt1, the enzyme that 
maintains DNA methylation patterns through mitosis in a somatic genome (Okano et al., 
1999). Dnmt1 knockout causes early embryonic lethality (Li et al., 1992), and 
conditional deletion of Dnmt1 is not tolerated in somatic cell types (Jackson-Grusby et 
al., 2001), indicating the importance of maintaining global DNA methylation patterns in 
cellular differentiation and identity.  
A variety of covalent modifications to histone proteins that compact DNA into 
nucleosomes is another important signature of cell identity (Wang et al., 2004). The N- 
and C-terminal tails of histone H3 are extensively methylated, acetylated, 
phosphorylated and ubiquinated in a complex manner reflective of the transcriptional 
status at the region. For example, pluripotent stem cells contain a characteristic 
chromatin signature, termed ‗bivalent domains‘(Bernstein et al., 2006 and 2007) —that 
is, enriched for both activating histon H3 lysine 4 trimethylation (H3K4me3) and 
repressive histone H3 lysine 27 trimethylation (H3K27me3) modifications (Mikkelsen et 
al., 2007).  First, Lender and colleagues identified a bivalent feature specific to ESC, 
while differentiated cells either had a univalent state or lost both marks, using 
chromatin-immunoprecipitation (ChIP) followed by hybridization to microarrays (ChIP- 
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Chip). Later, using ChIP-seq (chromatin-immunoprecipitated DNA followed by high-
throughput sequencing technology), Mikkelsen and colleagues demonstrated that 
bivalent domains are indicative of genes that remain in a poised state. Although 
pluripotent cells contained high numbers (~2500) of bivalent domains, multipotent 
neural progenitor cells (NPCs) that were more differentiated than ESCs remained 
bivalent (~200), indicating that they still retain the lineage of choice (Meissner et al., 
2008). These results are consistent with the involvement of histone epigenetic 
modifications in determining cell fate.  
 
Overcoming Epigenetic roadblocks 
For a detailed description of the epigenetic status of cells at different stage of 
development in Waddington‘s epigenetic landscape model, totipotent zygotes have 
global DNA demethylation. Pluripotent cells, such as ESCs or iPSCs, have in general 
hypomethylated promoter and global repression of differentiation genes by Polycomb 
proteins, whereas differentiated cells have hypermethylated promoters and de-repressed 
lineage genes (Waddington, 1957). The epigenetic status of differentiated somatic cells 
and pluripotent stem cells is largely different. Therefore, reprogramming differentiated 
somatic cells to pluripotency may provide active mechanisms by which epigenetic 
modifications are reversed, although the barrier is formidable.    
To achieve the pluripotent state from somatic cells, extensive remodeling of 
epigenetic marks that control access to genes and regulatory elements in the genome are 
essential. The re-establishment of H3K4me3 and the loss of DNA methylation in ‗ES- 
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cell-associated transcript‘ (ECAT) genes, such as Oct4 and Nanog, seem to be a critical 
and potentially rate-limiting step during reprogramming (Mikkelson et al., 2008). ECAT 
genes are activated at high levels and hypomethylated at their promoters in pluripotent 
cells, whereas hypermethylated in somatic cells, reflecting their transcriptionally 
repressed state (Imamura et al., 2006). The repression of these ECAT genes and high 
levels of methylation of their promoters contributes to a loss of pluripotency (Imamura 
et al., 2006). Conversely, the formation of iPSCs involves activation of these genes and 
demethylation of their promoters. This difference has become widely used to monitor 
successful reprogramming (Mikkelson et al., 2008). Therefore, the loss of DNA 
methylation in pluripotency genes is a critical step to achieve complete reprogramming.  
As proven by the high resolution of current techniques, the epigenetic status of 
iPSCs and ESCs are highly similar. It is clear that the chromatin signatures reset to an 
ESC-like pattern during iPSC reprogramming. Despite various trials that we discussed 
above to improve the efficiency of reprogramming, it is still very low, indicating the 
high epigenetic barriers in changing the epigenetic marks of somatic cells to pluripotent 
ES-like cells may be a limitation. Thus, the first approach that many research groups 
have tried is to lower the epigenetic barriers of reprogramming by chromatin 
modifications.  
To lower the epigenetic barrier, many efforts have been made in using various 
chromatin modifiers—histone deacetylase inhibitors (Butyrate, Valproic acid, TSA), 
histone methyltransferase inhibitor (BIX-01294), and DNA methyltransferase inhibitor 
(5-azacytidine). Higher levels of histone acetylation are generally associated with  
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increasing gene expression and open chromatin structure. Accordingly, genome-wide 
gene expression profiling on early reprogramming cells treated by, for example Butyrate, 
confirmed upregulated expressions of genes that are highly expressed in ESCs (Liang et 
al., 2010). Blunt treatment of histone deacetylase inhibitors raise the global levels of 
histone acetylation, resulting in increasing the efficiency of the reprogramming process. 
Especially, treatment with Valproic acid (VPA) lowered the barrier of reprogramming 
by enhancing the efficiency over 100-fold and even replaced viral cMyc in mouse, and 
CMYC and KLF4 in human cells (Haunfu, 2008a and 2008b), indicating that specific 
reprogramming factors could be eliminated, when acetylation levels were increased in 
cells by modulating the levels of histone acetylation. However, the identity of specific 
acetyltransferases involved in the modulation of the reprogramming process and the 
mechanism underlying the enhancement of iPSC generation are still unclear.  
 Another histone modifier, the small molecule named BIX-01294 thought to 
target the repressive histone H3K9 methyltransferase G9a, could also facilitate the 
reprogramming process (Shi et al., 2008a). A well-known inhibitor of DNA 
methyltransferase, 5-azacytidine (AZA), rescued trapped partially reprogrammed cells to 
iPSCs by overcomeing the roadblock of iPSC reprogramming (Mikkelson et al., 2008). 
Overabundant repressive modifications with these inhibitors of transcriptional repressors 
lead to successful iPSC generation, however, we do not know their key targets during 
reprogramming.  
The key repressive chromatin regulator proteins in normal development are 
Polycomb group (PcG) proteins that form multi-protein complexes and work as  
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transcriptional repressors of several thousand genes governing differentiation pathways 
during development (Morey and Helin, 2010). ESCs lacking the function of either 
Polycomb-repressive complex 1 (PRC1) or PRC2 differentiate into cells of the three 
germ layers, whereas simultaneous loss of PRC1 and PRC2 abrogates differentiation 
(Leeb et al., 2010). It has not been addressed whether PcG proteins affects iPSC 
reprogramming, however, it will be interesting to determine whether over-expression of 
PcG proteins could enhance reprogramming by reducing apoptosis, because PcG 
proteins maintain the silencing of key senescence regulating genes, such as Ink4/Arf, 
whose depletion promotes reprogramming (Banito et al., 2009; Hong et al., 2009; 
Kawamura et al., 2009; Li et al., 2009; Marión et al., 2009; Utikal et al., 2009).  
In spite of these diverse treatments, the identity of the major chromatin-
modifying and chromatin-binding factors involved in the iPSC conversion process is not 
yet known. Only recently, functional links between specific epigenetic modifiers and 
members of ESC core transcriptional networks in ESCs have come to light. WD repeat 
domain 5 (Wdr5), a core member of the mammalian Trithorax (TrxG) complex and an 
effector of H3K4 methylation, interacts with the pluripotency transcription factor Oct4 
(Ang et al., 2011).The Oct4-Sox2-Nanog circuitry and TrxG cooperately activate 
transcription of key regulators of self-renewal. Furthermore, Wdr5 expression is 
required for efficient iPSC generation. This provides an insight to how transcriptional 
regulators of pluripotency may cooperate with epigenitic modulators to regulate the 
balance between self-renewal and differentiation.  
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iPSCs Application from Laboratory to Patients 
Generating Disease-relevant Cell Types in vitro 
For many years, work has been executed to convert pluripotent cells into target 
cell types. The process of guiding the differentiation of ESCs or iPSCs to target cells, 
named directed differentiation, is a simulation of natural development in a culture dish 
through successive stages of cell fate specification (Gaspard and Vanderhaeghen, 2010; 
Murry and Keller, 2008; Peljto and Wichterle, 2011; Schwartz et al., 2008). By 
stimulating extracellular signaling molecules, using the same morphogens that mediate 
the corresponding transitions in vivo, pluripotent cells can be guided to change from one 
cell to another until it reaches the target cells.  
By identifying developmental signals, the directed differentiation protocols that 
turn ESCs into numerous cell types that represent all three germ layers have been 
developed. The addition of factors, such as bone morphogenic protein (BMP) 4, in 
serum free media directs mesodermal specification in ESCs (Dambrot et al., 2011; 
Murry and Keller, 2008). Further manipulation of this protocol generates many 
mesodermal cell types including hematopoietic cell types (Lengerke and Daley, 2010), 
cardiomyocytes (Dambrot et al., 2011), skeletal myoblasts (Barberi et al., 2007), and 
chondrocytes (Oldershaw et al., 2010; Toh et al., 2010).  
To produce cells of the endodermal lineage, Activin A is first used to direct 
ESCs toward definitive endodermal fate. Insulin-producing pancreatic β-cells, the cell 
type lost in type I diabetes, have been derived by directed differentiation by sequentially 
converting the cell fates in a stepwise fashion. When Activin A is followed with retinoic  
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acid (RA), NOGGIN, and cyclopamine to block Sonic Hedgehog (SHH) signaling, 
definitive endoderms are switched to a pancreatic progenitor state (Borowiak and 
Melton, 2009; Kroon et al., 2008). Further effort to identify small molecules by chemical 
screening has been attempted to achieve a pancreatic endocrine cell fate (Chen et al., 
2009). Likewise, it is possible to generate hepatocytes from definitive endoderm by the 
exposure of FGF 10 and RA for hepatic specification, and final maturation with 
fibroblast growth factor (FGF) 4, hepatocyte growth factor (HGF), and epidermal 
growth factor (EGF) (Basma et al., 2009; Hay et al., 2008; Touboul et al., 2010).  
Ectodermal fate is considered the default differentiation path taken by pluripotent 
cells in the absence of other extrinsic signals that bias cells toward mesodermal and 
endodermal states (Levine and Brivanlou, 2007). Therefore, by blocking both 
Activin/Nodal/Tgf-β and BMP signaling, stem cells can be differentiated into 
neuroectodermal cells in vitro (Chambers et al., 2009). Motor neurons, whose loss in a 
variety of genetic and sporadic diseases or injury leads to paralysis, are one of the first 
neural types that were produced by directed differentiation; RA guides neural 
progenitors to a spinal character (Wichterle et al., 2002), then SHH induces them to a 
ventral neural cell fate (Jessell, 2000). The resulting differentiated cells eventually 
contribute a significant portion of functional motor neurons because motor neurons 
originate from one of the most ventral regions of the developing neural tube (Boulting et 
al., 2011; Lee et al., 2007). Dopaminergic neurons, which are lost in Parkinson‘s disease, 
can also be derived from pluripotent cells using SHH and FGF8, which induce neural 
progenitor cells (NPCs) with a mid-hindbrain character (Perrier et al., 2004).   
 
27 
 
To apply the iPSC technology in the field of regenerative medicine, many groups 
have generated patient-specific, disease-relevant cell types, although there are significant 
issues such as low efficiency for differentiation of desired cell type and safety concerns 
for patient application (Boulting et al., 2011; Brennand et al., 2011; Dimos et al., 2008; 
Ebert et al., 2009; Ku et al., 2010; Lee et al., 2009; Liu et al., 2010; Marchetto et al., 
2010; Maehr et al., 2009; Park et al., 2008; Rashid et al., 2010; Seibler et al., 2011; 
Soldner et al., 2009; Zhang et al., 2010). The progress of iPSC reprogramming as 
discussed previously, coupled with further optimization of in vitro differentiation 
protocols may be necessary to derive cell types that are clinically relevant for future 
transplantation. 
 
Medical Applications of iPSCs to Patients  
The identification and generation of a disease-relevant cellular pathology offers 
unprecedented opportunities for modeling human disease in vitro, as well as platforms 
for discovering drugs in the most relevant cellular context. In addition, reprogramming 
technology and iPSCs have the potential to be used to model and treat human disease. 
Because animal models that have been generated to study human genetic 
diseases often do not recapitulate the whole spectrum of disease symptoms or have 
difficulty in finding therapies for patients, in vitro disease modeling using iPSCs derived 
from disease-specific patient cells has been encouraging. This approach can benefit for 
idiopathic diseases with no known genetic cause, or that has been difficult to study due 
to the inaccessibility of the defected cells from live patients for many neuronal disorders.  
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Using iPSC technology, research groups have investigated patients‘ genetic background 
as well as disease progress from their early stages by differentiating into disease-relevant 
target cells from patient iPSCs, thereby elucidating the common mechanisms leading to 
illness. Furthermore, potential drugs that could correct a disease can be screened on the 
disease affected cell type, aiding in the discovery of novel therapeutic compounds. 
Many iPSC lines have already been derived from patients from various diseases, 
including spinal muscular atrophy (SMA), familia dysautonomia, rett syndrome, fragile 
X syndrome, Parkinson‘s disease, amyotrophic lateral sclerosis (ALS), liver disorder, etc 
(Boulting et al., 2011; Ebert et al., 2009; Lee et al., 2009; Marchetoo et al., 2010; Park et 
al., 2008; Rashid et al., 2010; Soldner et al., 2009; Urbach et al., 2010).  
One of the first iPSC lines that has been used for in vitro disease modeling is 
from SMA patients‘ fibroblasts (Ebert et al., 2009). SMA is an autosomal recessive 
childhood neuromuscular disease that is characterized by the loss of lower motor 
neurons, and is caused by a decrease in levels of survival of motor neuron (SMN) 
protein due to mutation in the SMN1 gene with unknown mechanism (Burghes and 
Beattie, 2009; Ebert and Svendsen, 2010). iPSC lines from a patient with SMA indeed 
showed the reduced numbers of motor neurons at later time points, demonstrating the 
process of iPSC reprogramming and directed differentiation recapitulated disease 
phenotypes.  
Two compounds, tobramycine and VPA are known to increase the number of 
full-length SMN transcripts from the SMN2 locus in patient-derived iPSCs (Brichta et al., 
2003; Sumner et al., 2003). However, it remains to be addressed whether these  
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compounds could elevate SMN levels in motor neurons, thereby rescuing the motor 
neuron loss. In the past, researchers have screened to discover chemical compounds that 
may elevate SMN levels using various engineered cell lines and patient fibroblasts that 
are easily accessible. However, these compounds have failed in the clinic, possibly 
because the mechanisms that control the levels of SMN protein in human fibroblasts are 
substantially different from those in the target disease cell type, human motor neurons, 
in vivo. Therefore, further chemical screening may aid to identify disease-specific drugs 
that could have the same effect in motor neurons and thus rescue motor neuron death in 
patients. 
 Recently, patient iPSC-derived neurons from familial Parkinson‘s disease, 
which is caused by the progressive loss of midbrain dopaminergic neurons have been 
used to model the disease in vitro (Seibler et al., 2011; Nguyen et al., 2011). Familial 
Parkinson‘s disease patients carry mutations in the gene encoding PTEN-induced 
putative kinase 1, an outer mitochondrial membrane protein, or leucine-rich repeat 
kinase 2, which is the most common cause of familial Parkinson‘s disease. In such a 
case in which the disease-causing mutation is known, gene targeting could be used to 
repair disease-causing mutation in the DNA sequence. For precise gene targeting, new 
techniques have been developed to make the process more efficient by employing zinc 
finger nucleases that decrease the risk of off-target genetic mutation, resulting in safely 
repaired iPSCs (Zou et al., 2009). The gene-corrected patient-specific iPSCs could 
generate the healthy midbrain dopaminergic neurons through in vitro directed 
differentiation process and be transplanted into the patient‘s brain. Therefore, define- 
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factor reprogramming to pluripotency could have a broad impact from the laboratory to 
the clinic. Compared to SCNT or ESC fusion, it is the most practical approach by far for 
the generation of patient-specific iPSCs that can provide an unlimited cellular resource 
for regenerative medicine.   
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Summary 
The years since Takahashi and Yamanaka‘s groundbreaking discovery have seen 
enormous advance for the safety and efficacy of iPSC reprogramming technology. The 
first iPSCs were generated by co-transduction with viruses that express 24 
reprogramming factors. Subsequent experiments narrowed the required factors down to 
four. Further efforts by starting with different somatic cells, for example, NSCs other 
than fibroblasts enable the reduction of factors down to one, Oct4. For clinical 
application in the future, the dangerous retrovirus methods needed to be modified. 
Although various approaches including plasmid, protein, small molecule, etc. had been 
made, completely transgene-free or high efficiency was a challenge. Recently, the goal 
toward transgene-free iPSC generation was eventually achieved by using modified RNA 
encoding the reprogramming factors. However, the RNA technology still has some 
disadvantages—costly, laborious, and technically challenging. 
Reversing the normal developmental state carries formidable epigenetic barriers. 
However, iPSCs, which closely resemble ESCs in epigenetic signatures could overcome 
these barriers to gain pluripotency. Despite rapid progress in lowering epigenetic 
barriers by chromatin modifications during iPSC reprogramming, many mechanistic 
understandings of the epigenetic processes leading to pluripotency still remain questions.   
Thus, it will now be interesting to explore new approaches to develop and 
understand iPSC reprogramming by asking the following questions. For example, which 
somatic cells are the best sources for iPSCs for clinical application? Is there any other 
system, such as modulating developmental signaling, which can replace factors and  
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promote the efficiency? If DNA methylation is a final critical step to convert the somatic 
cells to iPSCs, does reducing DNA methylation significantly change the reprogramming 
dynamic? Our future efforts to answer these questions may provide better platforms for 
studying the mechanism, and move the field one step closer to clinical application. 
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Chapter 2  
 
Notch Inhibition Renders Both Oncogenic Transgenes and p53 
Inhibition Dispensable During iPSC Reprogramming 
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Abstract 
 
The reprogramming of somatic cells to pluripotency using defined transcription 
factors holds great promise for biomedicine. However, reprogramming remains 
inefficient and relies either on the use of the potentially dangerous oncogenes KLF4 and 
CMYC or the genetic inhibition of the tumor suppressor gene p53 (Hong et al., 2009; 
Kawamura et al., 2009; Li et al., 2009; Marion et al., 2009; Nakagawa et al., 2008; Okita 
et al., 2011; Utikal et al., 2009). We hypothesized that modulation of signal transduction 
pathways that control proliferation and differentiation of the target somatic cell during 
development might increase their reprogramming potential and provide an alternative to 
the genetic manipulation of pathways that control cellular transformation.  Here, we 
show that inhibition of the Notch pathway significantly improves the efficiency of 
reprogramming both mouse and human keratinocytes to pluripotency. Pharmacological 
inhibition of Notch enabled us to routinely produce mouse and human iPSCs without the 
use of the oncogenes KLF4 and CMYC while leaving p53 activity intact. Our findings 
demonstrate that controlling signal transduction cascades in the target somatic cell 
population can enhance their potential for reprogramming.  
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Introduction 
Use of the potent oncogenes KLF4 and CMYC in the generation of induced 
pluripotent stem cells (iPSCs) limits their translational utility. Currently, elimination of 
these genes during reprogramming requires suppression of p53 activity (Kawamura et al., 
2009; Okita et al., 2011), which permits the accumulation of genetic mutations in the 
resulting iPSCs (Marión et al., 2009). Therefore, there remains a real need for 
reprogramming approaches that enable iPSC generation without the use of KLF4 and 
CMYC while leaving p53 activity intact.  
Chemical screens have identified small molecules that enhance reprogramming 
by modulating cell signaling in partially reprogrammed intermediates (Ichida et al., 2009) 
or by reinforcing the pluripotency network (Silva et al., 2008; Zhu et al., 2010). 
However, it is unclear if the signal transduction cascades in target somatic cell 
populations can be modulated in such a way as to enhance their potential for 
reprogramming. If so, this might provide new strategies for expanding the translational 
utility of lineage conversion both in vitro and in vivo.  
The Notch signaling pathway is highly conserved and regulates the proliferation 
and differentiation of various progenitor cell types in many multicellular organisms 
(Artavanis-Tsakonas et al., 2010). Although it is recognized that the extent of cellular 
differentiation and proliferative capacity of a given somatic cell are important 
determinants of the efficiency by which it can give rise to iPSCs (Eminli et al., 2009; 
Hanna et al., 2009; Utikal et al., 2009), it has not been investigated whether forcing a 
population of somatic cells into a more potent ―stem cell‖ state can increase its  
 
48 
 
reprogramming potential. Furthermore, the effects of modulating Notch signaling on 
reprogramming have yet to be investigated in any context. 
As Notch signaling has been shown to induce the differentiation and reduce the 
proliferation of keratinocytes in vivo (Lefort et al., 2004; Rangarajan et al., 2001), we 
hypothesized that inhibition of Notch during keratinocyte reprogramming might promote 
the conversion of these somatic cells into iPS cells. We felt that keratinocytes were an 
attractive model system for such reprogramming studies as, if Notch inhibition did have 
a substantial effect on the reprogramming of this readily accessible cell type, it could be 
immediately translated to the production of patient-specific pluripotent stem cells 
(Aasen et al., 2008; Aasen et al., 2010). 
 
Results 
DAPT Promotes Mouse Keratinocyte Reprogramming and Enable to Generate iPSCs 
without Klf4 and cMyc. 
Notch signaling is activated by the -secretase complex, which cleaves the 
membrane-bound Notch receptor upon ligand binding and generates a free intracellular 
domain that translocates to the nucleus and modulates transcription (Artavanis-Tsakonas 
et al., 2010). It has previously been shown that the -secretase inhibitor DAPT can block 
Notch signaling in mouse keratinocytes
 (Blanpain et al., 2006). Consistent with previous 
findings, when we transduced neonatal mouse keratinocytes with the iPSC 
reprogramming factors and treated them with 10 M DAPT, we observed a significant 
increase in the abundance of the full-length Notch receptor, a reduction of the cleaved  
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Notch intracellular domain (NICD) (Figure 2.1a), and decreased transcription of Notch-
dependent target genes Hey1, Hes1, Hes5, and Col6a1 (Figure 2.1b).  
To determine whether inhibition of Notch could increase the efficiency of 
reprogramming, we transduced Oct4::GFP mouse keratinocytes with Oct4, Sox2, Klf4, 
and cMyc and cultured the resulting cells for 25 days either in the presence or absence of 
DAPT. We found that the addition of 10 M DAPT led to a significant, 4-fold increase 
in the number of resulting GFP+ iPSC colonies (Figure 2.1c).  
Because a previous study had shown that similar increase in reprogramming 
efficiency provided by suppression of p53 activity allowed the generation of iPSCs from 
keratinocytes without Klf4 and cMyc (Kawamura et al., 2009), we wondered whether 
DAPT treatment might also replace these factors. Indeed, although transduction of Oct4 
and Sox2 were not sufficient to induce mouse keratinocyte reprogramming, when they 
were combined with DAPT treatment, iPSC colonies were routinely obtained (Figures 
2.1d-e). This effect was specific to Oct4 and Sox2-transduced cells as other 2-factor 
combinations of factors did not yield iPSCs (Figure 2.1d).  The mouse iPSCs generated 
without Klf4 and cMyc harbored only the Oct4 and Sox2 transgenes (Figure 2.1h) and 
when injected into blastocysts contributed to the development of chimeric mice (Figure 
2.1f), including to their germ-line (Figure 2.1g), confirming their pluripotency. 
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Figure 2.1. DAPT treatment promotes mouse keratinocyte reprogramming.  
a, Western blot for Notch1 on OCT4, SOX2, KLF4, and CMYC-transduced mouse keratinocytes 
with or without 10 M DAPT treatment for 3 days. An increase in full-length Notch and a 
decrease in Notch intracellular domain (Notch ICD) levels is apparent. Lines representing the 
molecular weight markers are shown on the right.  b, QPCR analysis for the expression of 
Notch-dependent genes in mouse keratinocytes transduced with the reprogramming factors +/- 
10 M DAPT treatment for 3 days.  c, The efficiency of Oct4::GFP+ iPSC generation from 
mouse keratinocytes transduced with Oct4, Sox2, Klf4, and cMyc with or without 10 M DAPT 
treatment from days 1-18 of reprogramming.  d, The efficiency of Oct4::GFP+ iPSC generation 
from mouse keratinocytes transduced with all combinations of 2 reprogramming factors with or 
without 2.5 M DAPT treatment from days 1-18 post-transduction.  e, A P0 mouse iPSC colony 
generated using OCT4, SOX2, and DAPT, scale bars = 100 μm.  f, A chimeric mouse generated 
from C57BL6 OCT4, SOX2 + DAPT miPSCs injected into ICR (albino) blastocysts. Black coat 
color is derived from the miPSCs.  g, The E13.5 genital ridge of an embryo derived from non-
transgenic blastocysts injected with OCT4, SOX2 + DAPT miPSCs derived from Oct4::GFP 
keratinocytes. Oct4::GFP+ cells are found in the genital ridge, indicating that the miPSCs 
contribute to the germ line. h, iPSCs generated with Oct4, Sox2 and DAPT do not contain Klf4 
or cMyc transgenes. Genomic DNA was isolated from mouse keratinocyte-derived iPSC lines 
and probed for transgenic insertions by PCR using primers specific for the viral reprogramming 
genes. Lines representing the molecular weight markers are shown on the right. For all 
experiments, error bars represent the standard deviation between two biological replicates and 
statistical significance was determined using a two-tailed homoscedastic Student‘s t-test. 
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Figure 2.1 (Continued). 
 
  
 
52 
 
DAPT Improves the Reprogramming of Human Neonatal and Adult Keratinocytes 
into iPSCs and Replace KLF4 and cMYC. 
Since the role of NOTCH in antagonizing the proliferation and self-renewal of 
keratinocytes is conserved from mouse to human (Nguyen et al., 2006), we next asked 
whether chemical inhibition of NOTCH could also promote the reprogramming of 
human keratinocytes into iPSCs. DAPT treatment of human neonatal keratinocytes that 
had been transduced with the iPSC reprogramming factors greatly reduced the amount 
of NOTCH intracellular domain (Figure 2.2a) and the transcription of the NOTCH target 
genes HES1 and HES5 (Figure 2.2b).  When we transduced the human keratinocytes 
with reprogramming viruses and then administered DAPT, we observed a dose-
dependent increase in the number of presumptive iPS cell colonies that expressed 
NANOG and Tra1-81 (Figure 2.2c).  Similarly to the mouse keratinocytes, when we 
attempted to reprogram human keratinocytes with only OCT4 and SOX2 alone, iPSC 
colonies did not form (Figure 2.2d). However, when OCT4 and SOX2 were combined 
with DAPT treatment, presumptive human iPSC colonies expressing both NANOG and 
TRA-1-81 were readily observed (Figure 2.2d). When these colonies were expanded in 
culture, the resulting human cell lines continued to express both NANOG and TRA-1-81 
(Figure 2.2e) suggesting that they were stable iPSCs that had been generated without 
KLF4 and CMYC (Figure 2.2f). To determine whether these cell lines were pluripotent, 
we subjected them to a ―scorecard‖ assay for pluripotency that we recently developed 
(Bock et al., 2011). We found that these presumptive human iPSC lines were indeed 
composed of pluripotent cells and that they performed comparably to human embryonic   
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Figure 2.2. DAPT treatment promotes human keratinocyte reprogramming.  
a, Western blot detecting Notch intracellular domain (Notch ICD) expression levels in OCT4, 
SOX2, KLF4, and CMYC-transduced human keratinocytes +/- DAPT or DBZ treatment for 3 
days. Lines representing the molecular weight markers are shown on the right.  b, QPCR 
analysis for mRNA levels of NOTCH-dependent genes in human keratinocytes transduced with 
the reprogramming factors with or without 10 M DAPT treatment for 3 days.  c, The efficiency 
of NANOG+/ TRA-1-81+ iPSC generation from human neonatal keratinocytes transduced with 
OCT4, KLF4, SOX2, and CMYC and treated with different concentrations of DAPT from days 1-
18 post-transduction.  d, The efficiency of NANOG+/ TRA-1-81+ iPSC generation from human 
neonatal keratinocytes transduced with OCT4 and SOX2 and cultured in the presence or absence 
of 2.5 M DAPT from days 1-18 post-transduction.  e, NANOG+/TRA-1-81+ OCT4, SOX2 + 
DAPT iPSC line generated from human neonatal keratinocytes, scale bars = 100 μm.  f, iPSCs 
generated with OCT4, SOX2 and DAPT do not contain KLF4 or CMYC transgenes. Genomic 
DNA was isolated from human keratinocyte-derived iPSC lines and probed for transgenic 
insertions by PCR using primers specific for the viral reprogramming genes. Lines representing 
the molecular weight markers are shown on the right. g, Lineage scorecard analysis of embryoid 
bodies differentiated for 16 days, performed as described (Bock et al., 2011). The analysis shows 
that the adult and neonatal human keratinocyte-derived iPSC lines generated with OCT4, SOX2, 
and DAPT differentiate into endodermal, mesodermal, and ectodermal cells with propensities 
similar to other human pluripotent stem cell lines. The symbols indicate how this cell line 
compares to a reference set of 20 ESC lines for each of the dimensions covered by the lineage 
scorecard.  h, Hierarchical clustering of NanoString mRNA expression profiles of DAPT iPSC 
lines. Hierarchical clustering of mRNA expression profiles of pluripotent stem cell lines was 
performed as described (Bock et al., 2011) The OCT4, SOX2, DAPT iPSCs derived from human 
keratinocytes are compared with other human pluripotent stem cell lines such as ESC (hES) and 
fibroblast- (hiPS) and keratinocyte-derived iPSC lines induced with OCT4, SOX2, and KLF4 
(nkiPSOSK50). Primary fibroblast lines (hFib) and hESC-derived motor neurons (hMN) are also 
included. "nkiPS OSDAPT58" is a human iPSC line generated from neonatal keratinocytes with 
OCT4, SOX2, and DAPT. "nkiPS OSDAPT58s2," is a subclone from passage 2 of hkiPS 
OSDAPT58. "akiPS OSDAPT2" and "akiPSOSDAPT9" are two independent iPSC lines derived 
from adult keratinocytes using OCT4, SOX2, and DAPT. i, Teratomas containing differentiated 
cells of all three germ lineages generated by iPSC derived from human neonatal kerationcytes 
using OCT4, SOX2, and DAPT, scale bar = 50 m.  j, The efficiency of NANOG+/ TRA-1-81+ 
iPSC generation from human adult keratinocytes transduced with OCT4, KLF4, SOX2, and 
CMYC and treated with or without 10 M DAPT from days 1-18 post-transduction.  k, The 
efficiency of NANOG+/ TRA-1-81+ iPSC generation from human adult keratinocytes 
transduced with OCT4 and SOX2 and cultured in the presence or absence of 2.5 M DAPT from 
days 1-18 post-transduction.  l, NANOG+/TRA-1-81+ iPSC line generated from human adult 
keratinocytes using OCT4, SOX2 + DAPT, scale bars = 100 μm. For all experiments, error bars 
represent the standard deviation between two or three biological replicates and statistical 
significance was determined using a two-tailed homoscedastic Student‘s t-test. 
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Figure 2.2. (Continued) 
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Figure 2.2 (Continued). 
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stem cells (ESCs) in their expression of pluripotency-associated genes and 
differentiation propensities into the three embryonic germ layers (Figures 2.2g-h). To 
confirm their differentiation capacity, we also injected the OCT4, SOX2 + DAPT cells 
into immunocompromised mice. We found that they readily formed teratomas 
containing differentiated cells (Figure 2.2i).  
Translational applications would require the DAPT-dependent generation of 
KLF4 and CMYC-free iPSCs from adult keratinocytes. Therefore, we determined if 
DAPT treatment increased the reprogramming potential of adult human keratinocytes. 
As with mouse and human neonatal keratinocytes, we found that DAPT treatment of 
KLF4, SOX2, OCT4, and CMYC-transduced adult human keratinocytes significantly 
improved their rate of reprogramming (Figure 2.2j) and also enabled the generation of 
iPSCs with just OCT4 and SOX2 (Figures 2.2k-l). The scorecard assay again verified 
that these 2-factor iPSCs were pluripotent (Figures 2.2g-h). Together, these results 
demonstrate that DAPT reliably enables the generation of bona fide mouse and human 
iPSCs from keratinocytes without KLF4 and CMYC. 
 
DAPT Enhances Reprogramming in Keratinocytes by Specifically Inhibiting Notch 
Signaling. 
Our results thus far suggest that antagonizing Notch signaling in keratinocytes 
may promote their conversion into iPSCs. To begin verifying that NOTCH was indeed 
the functional target of DAPT during reprogramming, we first tested a structurally 
distinct   
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-secretase inhibitor, DBZ (Fuwa et al., 2007), for activity in iPSC generation. When we 
treated human keratinocytes with DBZ, we observed significant reductions in the levels 
of the intracellular domain of the NOTCH receptor (Figure 2.2a) and the NOTCH-
dependent genes HES1 and HES5 (Figure 2.3a), indicating that chemical administration 
inhibited NOTCH signaling. Consistent with the notion that NOTCH inhibition was 
increasing the rate of reprogramming, DBZ significantly stimulated the formation of 
human iPSC colonies (Figure 2.3b).  
Both DBZ and DAPT could have effects on the processing of unidentified -
secretase substrates that are distinct from NOTCH, which might also impact 
reprogramming efficiency. If the beneficial effects of DAPT on reprogramming were 
being mediated through the specific inhibition of NOTCH signaling rather than through 
some other target of -secretase, then we reasoned that constitutive activation of 
NOTCH signaling should eliminate the beneficial effect of DAPT. Consistent with this 
notion, we found that the overexpression of the NOTCH intracellular domain (Figure 
2.3c) stimulated the expression of NOTCH-target genes (Figure 2.3d) and completely 
eliminated the positive effects of DAPT on reprogramming (Figure 2.3e). Conversely, 
we reasoned that antagonizing the transcriptional activity of NOTCH should increase the 
rate of keratinocyte reprogramming. Indeed, when we suppressed NOTCH activity by 
overexpressing a dominant-negative form of MAML1 (Figure 2.3f), a transcriptional co-
activator for NOTCH (Nam et al., 2003 and 2006), we observed a significant increase in 
iPSC generation from keratinocytes transduced with all four reprogramming factors 
(Figure 2.3g). Therefore, we conclude that the inhibition of NOTCH signaling can   
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Figure 2.3. -secretase inhibition promotes reprogramming by blocking Notch signaling 
early in reprogramming.   
a, QPCR analysis for mRNA levels of NOTCH-dependent genes in human keratinocytes 
transduced with the reprogramming factors with or without 2 M DBZ treatment for 3 days.  b, 
The efficiency of NANOG+/ TRA-1-81+ iPSC generation from human neonatal keratinocytes 
transduced with OCT4, KLF4, SOX2, and CMYC and treated with different concentrations of 
DBZ from days 1-18 post-transduction.  c, QPCR analysis for viral NOTCH intracellular domain 
(NICD) and total NOTCH ICD in human neonatal keratinocytes transduced with lentivirus 
encoding NOTCH ICD or GFP.  d, QPCR analysis of expression levels of NOTCH-dependent 
genes in human neonatal keratinocytes transduced with Notch ICD or GFP.  e, The efficiency of 
NANOG+/ TRA-1-81+ iPSC generation from human neonatal keratinocytes transduced with 
OCT, SOX2, KLF4, and CMYC and GFP or NOTCH ICD and treated with DMSO or 10 M 
DAPT from days 1-18 post-transduction. Cells were transduced with NOTCH ICD or GFP 
lentivirus 1 day after transduction with the reprogramming factors.  f, QPCR analysis of 
expression levels of NOTCH-dependent gene HES1 in human neonatal keratinocytes transduced 
with dominant-negative Mastermind-like-1 (dnMAML) or RFP.  g, The efficiency of NANOG+/ 
TRA-1-81+ iPSC generation from human neonatal keratinocytes transduced with OCT, SOX2, 
KLF4, and CMYC and RFP or dnMAML and treated with DMSO or 10 M DAPT from days 1-
18 post-transduction.  h, The efficiency of NANOG+/ TRA-1-81+ iPSC generation over a time 
course of 10 M DAPT treatment in mouse keratinocytes transduced with OCT4, SOX2, KLF4, 
and CMYC. ―pre-DAPT‖ denotes treatment from 6 days before transduction to 1 day before 
transduction, and ―long DAPT‖ denotes treatment from 6 days before transduction until 18 days 
post-transduction. For all experiments, error bars represent the standard deviation between two-
three biological replicates and statistical significance was determined using a two-tailed 
homoscedastic Student‘s t-test. 

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Figure 2.3 (Continued). 
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significantly increase the efficiency of reprogramming both human and mouse 
keratinocytes. 
 
-secretase Inhibition Functions Early in Keratinocyte Reprogramming  
We and others have previously identified small molecules that enhance iPSC 
generation by acting at late time points in the cell conversion process either on partially-
reprogrammed intermediates or the iPSCs themselves (Ichida et al., 2009; Maherali et al., 
2009; Silva et al., 2008; Zhu et al., 2010). In order to determine when Notch inhibition 
was required to promote reprogramming, we treated mouse keratinocytes with DAPT 
either before or both before and after transduction with all four iPSC factors. While 
treatment both before and after transduction yielded a 4-fold increase in iPSC generation, 
we found that pre-treatment alone resulted in a significant 2.5-fold enhancement in 
reprogramming efficiency (Figure 2.3h). These results indicate that DAPT can act on the 
starting keratinocytes to enhance their reprogramming potential.  
To more precisely pinpoint the effective post-transduction treatment window, we 
transduced human keratinocytes with KLF4, OCT4, SOX2, and CMYC and administered 
DAPT or DBZ from days 1-6, 6-11, 11-16, or 1-16 after viral infection (Figures 2.4a-c). 
Chemical inhibition of NOTCH signaling was most effective during early time points, 
significantly increasing iPSC generation when used from days 1-6 and 6-11 (Figures 
2.4b-c). In contrast, a later treatment from days 11-16 had little effect on reprogramming   
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Figure 2.4. Notch inhibition promotes keratinocyte reprogramming by enhancing 
proliferation. 
 
 
a, Schematic of the post-transduction DAPT treatment time course on human neonatal 
keratinocytes. b, the efficiency of NANOG+/TRA-1-81+ iPSC generation from human neonatal 
keratinocytes transduced with OCT4, SOX2, KLF4, and CMYC and treated with varied intervals 
of 10µM DAPT or c, 2µM DBZ. d, QPCR analysis of endogenous OCT4, SOX2, KLF4, and 
CMYC treated with DMSO or 10µM DAPT for 3 days. e, Colony forming assay on human 
neonatal keratinocytes. After DMSO or 10µM DAPT treatment, keratinocytes were re-plated at 
1000 cells/35mm dish and colonies were scored two weeks later. Colonies containing >35 cells 
were scored positive. f, Colony forming assay using human neonatal keratinocytes transduced 
with GFP or p21. g, The efficiency of NANOG+/TRA-1-81+ iPSC generation from human 
neonatal keratinocyts transduced with OCT4, SOX2, KLF4, and CMYC and GFP or p21 and 
treated with DMSO or 10µM DAPT from days 1-18 post-transduction. h, The efficiency of 
Oct4::GFP+ iPSC formation from MEFs transduced with Oct4, Sox2, Klf4 and cMyc and treated 
with DMSO or 10µM DAPT from days 1-18 post-transduction. For all experiments, error bars 
represent the standard deviation between two-three biological replicates and statistical 
significance was determined using a two-tail homoscedastic Student‘s t-test.  
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 (Figures 2.4b-c). Together, these results indicate that Notch inhibition can act on the 
starting keratinocytes and just after the initiation of transcription factor overexpression to 
enhance reprogramming. 
 
Notch Inhibition does not Activate the Expression of Endogenous Reprogramming 
Factors 
One way that Notch inhibition could promote iPSC formation is by activating the 
expression of the reprogramming transcription factors from their endogenous loci. 
However, when we treated human keratinocytes with DAPT and analyzed their gene 
expression, we found that levels of KLF4, OCT4, and CMYC actually decreased and 
SOX2 did not significantly change (Figure 2.4d), indicating that Notch inhibition does 
not facilitate reprogramming by activating these reprogramming genes. 
 
Notch Inhibition Promotes Keratinocyte Rreprogramming by Enhancing Proliferation. 
Previous studies have shown that the replicative potential of the starting somatic 
cells is a key determinant of iPSC reprogramming efficiency (Hanna et al., 2009;Utikal 
et al., 2009). Artificially delaying the onset of senescence by inhibiting the p53-p21 
signaling pathway with small RNAs promotes iPSC generation (Hong et al., 2009; 
Kawamura et al., 2009; Li et al., 2009; Marion et al., 2009; Okita et al., 2011; Utikal et 
al., 2009), possibly by creating more opportunities for reprogramming to successfully 
occur (Hanna et al., 2009; Utikal et al., 2009).   
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In the mammalian epidermis, Notch signaling regulates tissue development and 
homeostasis by inducing keratinocytes to exit the cell cycle and begin differentiating 
(Lefort et al., 2004). To determine if chemical inhibition of Notch signaling in 
keratinocytes might be enhancing their reprogramming potential by increasing their 
long-term proliferative capacity, we performed a colony-forming assay (Jones et al., 
1993) on DAPT- or DMSO-treated human keratinocytes (Figure 2.4e). The ability to 
form large colonies on collagen demonstrates the ability of keratinocytes to self-renew 
extensively and is a functional property unique to undifferentiated cells of this lineage 
(Jones et al., 1993). In contrast, differentiated keratinocytes senesce after only a few 
rounds of division and do not form colonies ( Jones et al., 1993). DAPT treatment of 
human keratinocytes for 6 days significantly increased the number of cells capable of 
forming large colonies when cultured for an additional 14 days in the absence of the 
chemical (Figure 2.4e). The resulting 4-fold increase in colony formation rate was 
similar in magnitude to the elevation in iPSC generation with DAPT treatment (Figure 
2.2c). To determine if this increased self-renewal capacity was indeed promoting 
reprogramming, we transduced keratinocytes with p21 to limit replication and attempted 
to reprogram them either with or without DAPT. The forced p21 expression severely 
impaired the self-renewal potential of the keratinocytes (Figure 2.4f) and inhibited iPSC 
formation after transduction with the four reprogramming factors and treatment with 
DAPT (Figure 2.4g).  
Because Notch inhibition does not promote fibroblast replication (Kavian et al., 
2010), if this is the mechanism by which DAPT improves reprogramming, we would not  
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expect chemical treatment to affect mouse embryonic fibroblast (MEF) reprogramming. 
Indeed, DAPT treatment of MEFs transduced with all four reprogramming factors did 
not affect the rate of iPSC generation (Figure 2.4h). Together, these results suggest that 
Notch inhibition promotes iPSC generation from keratinocytes at least in part by 
enhancing their long-term replicative potential. 
 
Synergism of DAPT and Inhibitor of DOT1L Highly Enhances Reprogramming with 
OCT4 and SOX2. 
Knowing that Notch inhibition enhances iPSC generation through this unique 
mechanism, we next wanted to compare its activity to previously described 
reprogramming molecules that act through other mechanisms (Huangfu et al., 2008; 
Mikkelsen et al., 2008; Onder et al., 2012; Zhu et al., 2010) and identify any that DAPT 
might synergize with. When we transduced human neonatal keratinocytes with KLF4, 
SOX2, OCT4, and CMYC and treated them with various combinations of compounds 
shown to enhance reprogramming in other reports, including an activator of 3‘-
phosphoinositide-dependent kinase-1 (PDK1) (Zhu et al., 2010), inhibitors of TGF-, 
MEK, and GSK3 signaling (Zhu et al., 2010), histone deactylase inhibitors (Huangfu et 
al., 2008; Zhu et al., 2010), histone methyltransferase inhibitors (Onder et al., 2012; Zhu 
et al., 2010), and a DNA methyltransferase inhibitor (Mikkelsen et al., 2008), we found 
that DAPT treatment was most potent at enhancing reprogramming (Figure 2.5a). This 
remained true when we attempted reprogramming with only OCT4 and SOX2 (Figure  
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Figure 2.5. Inhibition of NOTCH signaling and DOT1L activity synergize to enable high 
efficient reprogramming with OCT4and SOX2.  
 
 
a, Comparison of NANOG+/TRA-1-81+ iPSC generation from OCT4, SOX2, KLF4, and 
CMYC-transduced human neonatal keratinocytes using 10µM DAPT versus other published 
reprogramming chemicals. "A83"= A8301 (.5µM), "PD" = PD0325901 (.5µM), "All Zhu et 
al."= A8301 (.5µM), PD0325901 (.5µM), PS48 (5µM), sodium butyrate (.25mM), Parnate 
(2µM), CHIR99021 (3µM), "AZA"=5-Aza-cytidine (.5µM), "VPA"= valproic acide (.5mM), 
"iDOT1L" = EPZ004777 (3µM). b, Comparison of NANOG+/TRA-1-81+ iPSC generation 
from OCT4-, SOX2-transduced human neonatal keratinocytes using 2.5µM DAPT versus other 
published reprogramming chemicals. c, iPSC line generated from human neonatal keratinocyts 
using OCT4, SOX2, DAPT, and iDOT1L. Scale bars=100µm. For all experiments, error bars 
represent the standard deviation between three biological replicates in two-three individual 
experiments, and statistical significance was determined using a two-tailed homoscedastic 
Student‘s t-test.  
 
66 
 
2.5b). However, with only two factors, an inhibitor of the histone methyltransferase 
DOT1L (iDOT1L) synergized with DAPT to elevate the rate of iPSC generation by 10- 
fold over the rate with DAPT alone, making it more efficient than 4-factor 
reprogramming either with or without DAPT (Figure 2.5b). The OCT4 + SOX2 + DAPT  
+ iDOT1L colonies could be readily expanded and maintained NANOG and TRA-181 
expression (Figure 2.5c). These data indicate that Notch inhibition is a potent enhancer 
of reprogramming in keratinocytes that can synergize with chromatin-modifying 
compounds to induce pluripotency at a high efficiency with only OCT4 and SOX2. 
 
Inhibition of Notch Signaling Bypasses the Requirement of p53 Inhibition during 
iPSC Reprogramming  
Previous studies of p53 and p21 in reprogramming have suggested that ectopic 
overexpression of reprogramming transcription factors can activate p53, which then 
induces either apoptosis or the expression of p21, thus inhibiting reprogramming (Hong 
et al., 2009; Kawamura et al., 2009). Because suppression of this pathway greatly 
facilitates iPSC generation, this approach has become an important part of 
reprogramming methods that reduce or eliminate integrating exogenous transcription 
factors (Kawamura et al., 2009; Okita et al., 2011). However, because p53 inhibition 
allows the accumulation of genetic mutations during reprogramming (Marión et al., 
2009), alternative approaches for increasing reprogramming efficiencies would be more 
desirable. We therefore next asked whether Notch inhibition promotes reprogramming 
through a p53-dependent or independent pathway by analyzing the effects of DAPT and  
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DBZ treatment on p53 and several of its target genes. Interestingly, chemical inhibition 
of Notch signaling by DAPT or DBZ in human keratinocytes did not reduce the 
expression of p53 at the protein or mRNA level either before or after transduction with 
the reprogramming factors (Figures 2.6a-c). Moreover, transcriptional analysis of 
DAPT-treated human and mouse keratinocytes revealed that the mRNA levels of the 
p53 target genes Dr5, Puma, and Fas were not decreased (Figures 2.6b-d), indicating 
that p53 activity was not suppressed by Notch inhibition.  
To confirm that DAPT treatment did not suppress p53 activity, we performed 
reprogramming experiments with and without DAPT after UV irradiation. UV exposure 
causes DNA damage, which in turn reduces reprogramming efficiencies by inducing 
p53-dependent apoptosis (Marión et al., 2009). p53-deficient cells, however, are 
resistant to the negative effects of UV irradiation on reprogramming (Marión et al., 
2009). Therefore, if p53 activity was maintained in DAPT-treated cultures, then we 
would expect a sharp decrease in reprogramming efficiency after UV irradiation. As a 
control for p53-deficiency, we performed 4-factor reprogramming with or without UV 
irradiation using keratinocytes in which we overexpressed a dominant-negative form of 
p53 (p53DD) that suppressed p53 activity as evidenced by a decrease in the expression 
levels of p53-dependent target genes (Figure 2.6e). As expected, there was no difference 
in the rate of iPSC generation with or without UV exposure in this condition, indicating 
that p53 activity was indeed inactivated (Figure 2.6f). In contrast, without p53DD 
overexpression, UV exposure sharply reduced the number of iPSCs generated in 
DMSO-treated cultures (Figure 2.6f). Similarly, UV irradiation severely diminished the   
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Figure 2.6. NOTCH inhibition does not suppress p53 activity.   
a, Western blot of p53 levels in human neonatal keratinocytes with DMSO or 10 M DAPT 
treatment for 3 days.  b, QPCR analysis of p53-dependent genes after 10 M DAPT or 2 M 
DBZ treatment for 3 days in untransduced human neonatal keratinocytes.  c, QPCR analysis of 
p53-dependent genes after 10 M DAPT or 2 M DBZ treatment for 3 days in OCT4, SOX2-
transduced human keratinocytes.  d, QPCR analysis of p53-dependent genes after 10 M DAPT 
treatment for 3 days in OCT4, SOX2-transduced mouse neonatal keratinocytes.  e, QPCR 
analysis of p53-dependent genes in human neonatal keratinocytes with GFP or p53DD 
overexpression for 3 days.  f, The efficiency of NANOG+/TRA-1-81+ iPSC generation in 
human neonatal keratinocytes transduced with p53DD or GFP with or without exposure to UV 
irradiation.  g, H2AX immunostaining in human neonatal keratinocytes 10 days after 
transduction with OCT4, SOX2, KLF4, and CMYC.  h, Quantification of pan-nuclear H2AX 
immunostaining in human neonatal keratinocytes 10 days after transduction with OCT4, SOX2, 
KLF4, and CMYC.  i, The percentage of TUNEL-positive cells in human neonatal keratinocyte 
reprogramming cultures with active or inactive p53 (p53DD expression) 10 days after 
transduction with OCT4, SOX2, KLF4, and CMYC.  For all experiments, error bars represent the 
standard deviation between two biological replicates and statistical significance was determined 
using a two-tailed homoscedastic Student‘s t-test. * denotes significance p-value < .05.  ** 
denotes significance p-value < .01. 
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Figure 2.6 (Continued). 
 
 
 
 
 
 
 
 
 
  
 
70 
 
number of iPSC colonies in DAPT-treated cultures, indicating that Notch inhibition does 
not suppress p53 activity during reprogramming (Figure 2.6f).  
Although the difference in reprogramming efficiency in p53-deficient versus 
DAPT-treated keratinocytes was clearly evident when UV irradiation was used to induce 
DNA damage, we next determined whether DNA damage was measurably influenced by 
DAPT treatment under normal reprogramming conditions. To test this, we quantified 
phosphorylated histone H2AX (H2AX) expression in 4-factor-transduced human 
keratinocytes treated with DAPT or p53DD. Histone H2AX becomes phosphorylated in 
response to double strand DNA breaks, making it a reliable marker of DNA damage 
(Marión et al., 2009). Pan-nuclear H2AX expression results from replication-induced 
damage and therefore would indicate insults sustained during reprogramming (Marión et 
al., 2009). We found that 10 days after transduction, pan-nuclear H2AX staining was 
present at significantly higher numbers in p53-deficient cultures than control cultures, 
which is consistent with a previous study in which elevated rates of DNA damage was 
observed in p53-deficient cells during reprogramming and in the resulting iPSCs 
(Marión et al. 2009) (Figures 2.6g-h). The DAPT-treated cells, however, maintained a 
low fraction of cells with pan-nuclear H2AX expression that was similar to the control 
cultures (Figures 2.6g-h). These results suggest that, in contrast to p53-deficiency, 
DAPT treatment does not promote the survival and reprogramming of cells with DNA 
damage.  
To confirm that Notch inhibition does not prevent the apoptosis of compromised 
cells during reprogramming, we measured the fraction of TUNEL-positive nuclei in  
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DAPT-treated cultures. Despite high rates of DNA damage in the p53-deficient 
reprogramming cultures, the percentage of TUNEL-positive nuclei was greatly reduced 
compared to a wild-type control, indicating that inactivation of p53 likely permitted the 
survival of cells with compromised genomes (Figure 2.6i). In contrast, the percentage of 
TUNEL-positive cells was not significantly reduced by DAPT treatment (Figure 2.6i). 
Together, these experiments show that DNA damage is present during normal 
reprogramming conditions and that inhibition of p53 allows cells with damaged genomic 
material to persist. In contrast, DAPT-mediated Notch inhibition enhances 
reprogramming without facilitating iPSC generation from cells with compromised 
genomic integrity or promoting the survival of iPS cells that have undergone DNA 
damage. 
 
Discussion 
In summary, our findings suggest that signaling through the Notch pathway is a 
significant impediment to the early stages of the reprogramming of both mouse and 
human keratinocytes into iPSCs. Importantly, the mechanism by which Notch signaling 
likely inhibits reprogramming in both mouse and human is by limiting long-term self-
renewal through a p53-independent pathway. Consistent with this hypothesis, treatment 
of reprogramming cultures with the -secretase inhibitors DAPT and DPZ reduced the 
levels of intracellular Notch and increased colony forming potential, leading to an 
increase in the rate of iPSC formation. Importantly, the resulting improvement in  
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reprogramming activity and the ability to generate iPSCs without the oncogenes CMYC 
and KLF4 did not come at the expense of a reduction in p53 activity.  
Our findings therefore have immediate and practical ramifications for the 
improved production of patient-specific human iPSCs. When taken together, our studies 
show that through pharmacological inhibition of NOTCH, it is routinely possible to 
produce human iPS cells with only OCT4 and SOX2, rendering CMYC and KLF4 
dispensable and thereby reducing the oncogenic potential of the resulting cells. 
Furthermore, our findings enabled CMYC and KLF4-free iPSC production without 
inhibition of p53 or its target genes involved in apoptosis, allowing pro-apoptotic 
pathways that ensure genomic integrity to be engaged (Marión et al., 2009). Thus, in this 
approach, the production of oncogene free iPS cell lines does not come at the expense of 
an increase in mutational load (Gore et al., 2011; Marión et al., 2009).   
Our findings with Notch demonstrate that developmental signaling pathways can 
substantially modulate the reprogramming potential of somatic cells, affecting both the 
quality and quantity of the resulting cell conversions. Because this approach is based on 
the modulation of developmental and homeostatic signaling pathways, it may also 
enhance the plasticity of somatic cells in vivo, thereby enabling efficient reprogramming 
in situ for the regeneration of diseased or damaged tissues. These findings suggest that 
wider investigation of how such pathways modulate the outcome of reprogramming is 
warranted. 
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Methods Summary 
Oct4::GFP neonatal mouse keratinocytes were isolated from P1-P2 pups and 
cultured in SFM medium (Invitrogen) on collagen IV-coated plates. Neonatal human 
epidermal keratinocytes (Lonza) were cultured in Epilife medium (Invitrogen) on 
collagen-coated plates. Keratinocytes were reprogrammed using retroviruses containing 
OCT4, SOX2, KLF4, and CMYC produced in the pMXs backbone. Chemical treatment 
was initiated 1-2 days after viral transduction and re-administered every other day until 
the end of the experiment unless otherwise specified. DAPT was used at 10 M for 
reprogramming experiments using OCT4, SOX2, KLF4, and CMYC and 2.5 M for 
OCT4, SOX2 reprogramming experiments unless otherwise noted.  DBZ was used at 2 
M. Irradiated mouse embryonic fibroblast feeders were added 6 days after transduction 
and the media was changed to mouse or human embryonic stem cell medium at that time. 
Illumina MouseRef-8 microarrays were used for genome-wide mRNA expression 
analysis. SYBR green (Bio-rad) was used for QPCR analysis. Antibodies detecting 
mouse Notch (Santa Cruz Biotechnology, sc-6015) and cleaved human NOTCH (Cell 
Signaling Technology, 2421) were used for western blot analysis. Blots were quantified 
using ImageJ software. Antibodies specific for NANOG (Abcam, AF1997) and TRA-1-
81 (Chemicon, MAB4381) were used to identify human iPSCs. Nanostring and 
scorecard analysis was performed as described (Bock et al. 2011). In vitro 
differentiation, chimera, and teratoma assays were performed as described (Ichida et al. 
2009). UV irradiation was performed at a dosage of 30 J.  Notch antibodies (ab27526, 
Abcam and sc-23307, Santa Cruz) were used for western blots. A H2AX (Abcam,  
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ab11175) antibody was used to detect H2AX foci. Cells in which H2AX staining 
covered greater than half the nucleus were scored as positive for H2AX foci. TUNEL 
staining was performed using the TUNEL kit from Pharmacia Biosciences. 
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Chapter 3  
 
Reduction of DNMT1 protein enhances the kinetics and efficiency of 
iPSC reprogramming 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addendum 
 
This chapter is adapted from the original article: 
Julia E. Chung*, Camille Sindhu, Rahul Karnik, Zack Smith, Alexander Meissner, Kevin Eggan (2013). 
Reduction of DNMT1 protein enhances the kinetics and efficiency of iPSC reprogramming.  
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Abstract 
 
Reprogramming somatic cells into induced pluirpotent stem cells (iPSCs) by 
defined transcription factors holds great potential for biomedicine. However, the 
reprogramming process retains slow kinetics and low efficiency. Reprogramming of 
somatic cells into iPSCs resets the epigenome to an embryonic-like state, which includes 
DNA demethylation of somatically-methylated pluripotentcy genes. We hypothesized 
that lowering the activity of the DNA methyltransferase 1 (Dnmt1) gene might increase 
the reprogramming potential and perturb a blockade of iPSC reprogramming. Here, we 
have generated an allelic series of Dnmt1 mouse embryonic fibroblasts (MEFs), which 
have differentially modulated Dnmt1 expression, and investigated their reprogramming 
efficiency and dynamics. At the epigenetic level, methylation levels of Oct4 regulatory 
regions are decreased by 50% in hypomorphic Dnmt1MEFs, which reduces Dnmt1 
expression to 10% of wild-type levels, indicating that reducing Dnmt1unravels the 
repressive effect in the Oct4 region. We found that a 90% reduction in Dnmt1 levels 
enhanced the efficiency of reprogramming over 4-fold. Importantly, hypomorphic allele 
(Dnmt1
chip)
 transduced line, which induces relatively low expression levels (20-40%) of 
DNMT1are reprogrammed to pluripotency with high efficiency and fast kinetics by 
directly activating Oct4 expression and bypassing the intermediate states. Furthermore, 
DNA demethylation synergized with histone acetylation and histone demethylation 
increased their conversion rates over 100-fold. Our findings demonstrate that DNA 
demethylation, by decreasing Dnmt1 expression levels, can increase the reprogramming  
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potential of somatic cells. Collectively, our data offers new insights into the nature of 
epigenetic events inherent to cellular reprogramming.   
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Introduction 
Mouse and human somatic cells can be reprogrammed to induced pluripotent 
stem cells (iPSCs) by ectopic over-expression of four transcription factors (Oct4, Sox2, 
Klf4 and c-Myc) (Takahashi and Yamanaki., 2006). iPSC technology could be an 
attractive resource for patient-specific stem cells, however, the slow kinetics and low 
efficiency of reprogramming is a hurdle for iPSC generation. 
              The unique patterns of DNA methylation and histone modifications contribute 
to the epigenetic state of a cell, which is in part responsible for cell or tissue-specific 
gene expression. To achieve a pluripotent state during reprogramming, the removal of 
repressive DNA methylation at the promoter of pluripotency genes, such as Oct4 or 
Nanog is necessary, as well as appropriate histone modifications to activate pluripotency 
genes and to repress somatic genes (Lister et al., 2009; Mikkelesen et al., 2008). Thus, 
iPSC reprogramming must involve mechanisms responsible for changing the epigenetic 
status of both, DNA and histones genome-wide. Recently, it has been found that changes 
of DNA methylation occur predominantly at the end of reprogramming during the entire 
spectrum of iPSC generation, suggesting that DNA methylation changes are final critical 
events to convert the cell type (Polo et al., 2012). In this regard, we hypothesized DNA 
methylation may play a critical role in reprogramming.  
There are two major epigenetic regulatory systems that control DNA methylation 
patterns in somatic cells; DNA methyltransferase3a (Dnmt3a) and Dnmt3b mediate de 
novo DNA methylation during development, subsequently DNA methyltransferase1 
(Dnmt1) maintains DNA methylation patterns of somatic genome (Li et al., 1992; Okano  
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et al., 1999). Mouse embryonic fibroblasts (MEFs) that are deficient in the de novo DNA 
methytransferase Dnmt3a and Dnmt3b enable to reprogram to pluripotency with a 
similar efficiency of reprogramming with wild-type cells (Pawlak et al., 2011), 
suggesting that de novo DNA methylation is dispensable for iPSC reprogramming. 
However, knocking out Dnmt1 leads to embryonic lethality (Li et al., 1992) and is not 
tolerated in somatic fibroblasts (Jackson-Grusby et al., 2001), indicating the importance 
of maintaining global DNA methylation pattern for survival of somatic cells. 
Interestingly, it has been reported that transient inhibition of Dnmt1or treatment of DNA 
methyltransferase inhibitor 5-aza-cytidine (AZA) facilitates reprogramming of trapped 
intermediates (Mikkelesen et al., 2008), indicating that DNA demethylation of one or 
more (unknown) loci by reduced level of Dnmt1 is a critical step in the later stage of 
iPSC reprogramming, and inhibition of Dnmt1 lowers the kinetic barriers of 
reprogramming. Another supporting report for a hypomorphic Dnmt1 gene contribution 
in reprogramming is the hypomorphic allele of Dnmt1 donor fibroblasts increases the 
efficiency of embryonic stem cell (ESC) derivation by somatic cell nuclear transfer 
(Blelloch et al., 2006). Therefore, we need to understand how much levels of reduced 
Dnmt1 affects the efficient reprogramming process. 
Although AZA can be utilized to confer hypomethylation of DNA at low doses, 
it is cytotoxic to cells due to its incorporation into DNA or RNA and apparent 
interactions with protein biosynthesis. Therefore, it is difficult to measure the extent to 
which the Dnmt1 inhibition function of compound AZA treatment affects the efficiency 
of iPSC reprogramming. To understand how much of DNA hypomethylation achieved  
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by different levels of Dnmt1 expression contributes to reprogramming, we need to 
establish mice carrying differentially reduced levels of Dnmt1. Here, we have generated 
an allelic series of Dnmt1 Oct4::GFP reporter MEFs—with 100%, 60%, 50%, 20% and 
10% Dnmt1 expression levels compared to wild type MEFs—using a conditional 
mutation in the Dnmt1gene and a hypomorphic allele (Gaudet et al., 2003; Jackson-
Grusby et al., 2001), and converted them into iPSCs with four reprogramming factors. 
Using this transgenic approach, we have investigated whether the rate of iPSC 
generation was influenced by reducing Dnmt1 levels, and how the reprogramming 
processes was altered based on comparisons with the normal iPSC reprogramming 
trajectory. Although further studies of the global methylation status in the differentially 
modulated Dnmt1 cell lines are required, our findings give us insight into how 
significantly DNA demethylation, which lowers the epigenetic barriers, influences  in 
iPSC reprogramming.   
 
Results 
Generation of an Allelic Series of Dnmt1 Oct4::GFP reporter MEFs Offers Highly 
Modulated Dnmt1 Expression Level—100%, 60%, 50%, 20%, and 10% of Dnmt1 
Expression 
A mouse carrying a conditional mutation in the Dnmt1 gene, referred to as 
Dnmt1
1lox, has been reported which results in the deletion of the motif for localization 
and the entire catalytic domain of the protein upon Cre mediated recombination 
(Jackson-Grusby et al., 2001). A mouse carrying a hypomorphic Dnmt1 allele, Dnmt1
chip,  
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reduces Dnmt1 expression to 10% of wild-type levels and results in substantial genome-
wide hypomethylation in all tissue (Gaudet et al., 2003). Using this conditional mutation 
and a hypomorphic allele, we were able to generate mice carrying Dnmt1
chip/1lox; 
Oct4::GFP reporter compound heterozygotes with substantially reduced levels of Dnmt1.
  
First, we crossbreed Dnmt1
2lox/2lox with mice carrying homologous Cre alleles to generate 
Dnmt1
+/1lox. Next we mated these mice with Oct4::GFP homozygotes to create reporter 
mice, then crossed Dnmt1
+/1lox; Oct4::GFP with hypomorphic alleles Dnmt1
chip/chip to 
generate Dnmt1
chip/1lox; Oct4::GFP (Fig 3.1a). In addition, to generate 60% (Dnmt1
+/chip) 
and 20% (Dnmt1
chip/chip) Dnmt1 expressing MEFs, we crossed Dnmt1
+/chip; Oct4::GFP 
mice (Figure 3.1a). 
From these crossbreeding strategies, we created mice containing various 
combinations of the hypomorphic Dnmt1 allele and conditional mutant allele, including 
wild-type control: 100%, 60%, 50%, 20%, and 10% of Dnmt1 expression levels (Figure 
3.1a). We harvested wild-type Dnmt1, Dnmt1
+/chip, Dnmt1
+/1lox, Dnmt1
chip/chip and 
Dnmt1
chip/1lox; Oct4::GFP reporter MEFs from 13.5 day embryos. To confirm whether 
the genotyping results of the allelic series provides targets that express expected Dnmt1 
gene expression levels, we performed RT-qPCR for Dnmt1. Introduction of the Dnmt1 
mutation gradually decreased the levels of the Dnmt1 gene compared to wild-type 
control and mouse ESC control (Figure 3.1b-c). As expected, Dnmt1
chip/1lox MEFs have a 
90% reduction in Dnmt1 gene expression (Figure 3.1b-c). QPCR results for Dnmt1 
expression in exon 4 (Figure 3.1b) and exon 12-14 regions (Figure 3.1c) were highly 
similar, indicating that mutations of the Dnmt1 gene in MEFs are consistently well-   
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introduced. Next, to determine whether sequentially modulated Dnmt1 expression 
directly affects the amount of Dnmt1 protein expression, we performed Western blot 
analysis for Dnmt1 with protein extracts from each allelic series of MEFs. Consistent 
with the previous report (Gaudet et al., 2003; Jackson-Grusby et al., 2001), Dnmt1
chip/1lox 
MEFs have a highly reduced level of the DNMT1 protein, whereas Dnmt1
+/1lox MEFs 
express the DNMT1 protein at levels similar to wild-type control (Figures 3.1d-e and 
Table 3.1). Interestingly, all cell lines harboring the hypomorphic Dnmt1
chip allele, for 
example  Dnmt1
+/chip and  Dnmt1
chip/1lox MEF lines, have highly reduced protein levels of 
DNMT1as compared to wild-type control or Dnmt1
+/1lox MEFs (Figures 3.1d-e and 
Table 3.1). Although the gene expression level of Dnmt1
+/chip is 10% higher than that of 
Dnmt1
+/1lox MEFs as we modulated, the protein expression level of Dnmt1
+/chip MEFs 
were reduced more than 50% compared to Dnmt1
+/1lox MEFs (Figures 3.1d-e and Table 
3.1), indicating that Dnmt1
+/chip and Dnmt1
+/1lox MEFs might behave quite differently 
during the reprogramming process. 
 
Reduced Levels of Dnmt1Expression Unravel the Repressive Effect in Endogenous 
Oct4 Regulatory Regions 
During differentiation, the promoters of pluripotency genes become highly 
methylated through de novo methylation, ultimately reaching complete repression of the 
genes in somatic cells (Ben-Shushan et al., 1995; Gidekel et al., 2002). Global 
methylation patterns by Southern blot analysis of IAPs show extensive hypomethylation  
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Figure 3.1. The allelic series of Dnmt1;Oct4::GFP MEFs were sensitively modulated in 
Dnmt1 expressions.  
a, The cross-breed strategy generates the allelic series of Dnmt1Oct4::GFP reporter MEFs. b, 
QPCR analysis for the expression of Dnmt1 Exon 4 gene in the allelic series of Dnmt1 MEFs. 
The allelic series of Dnmt1 MEFs express gradually reduced levels of Dnmt1 mRNA expression 
as compared to wild-type control. c, QPCR for Dnmt1 Exon 12-14 regions in the allelic series of 
Dnmt1 MEFs. The overall Dnmt1 expression levels of Exon 12-14 are highly similar to that of 
Exon 4. d, Western blot for Dnmt1 on the allelic series of Dnmt1 MEFs. The chip gene 
transduced genotypes suppress Dnmt1 protein levels as compared to wild-type or Dnmt1
+/1ox 
genotype. Lines representing the molecular weight markers are shown on the left. e, 
Quantification of western blots for Dnmt1 on the allelic series of Dnmt1 MEFs. For all 
experiments, error bars represent the standard deviation between three biological replicates in 
three individual experiments, and statistical significance was determined using a two-tailed 
homoscedastic Student‘s t-test (p-value < .05). 
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Figure 3.1. (Continued) 
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Table 3.1. Comparison of projected levels of DNMT1 protein expression versus actual 
levels of DNMT1 protein expression.   
 
 
Genotype  Projected levels 
of DNMT1 % 
Actual levels 
of DNMT1 % 
Dnmt1
+/+                            100  100 (±0) 
Dnmt1
+/chip   60  40 (±13) 
Dnmt1
+/1lox (+/-)             50  84 (±10) 
Dnmt1
chip/chip   20  46 (±13) 
Dnmt1
chip/1lox 
(chip/-)   10  28 (±5) 
 
The projected levels of DNMT1 is estimated by the gene expression levels of Dnmt1, however 
the actual levels of DNMT1 measuared by Western blotting is not depended on the gene 
expressions. Any Dnmt1
chip allele introduced lines possess lower expression levels of DNMT1 
than wild-type MEFs. 
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in both Dnmt1 deficient ESCs and hypomorphic Dnmt1 MEFs (Gaudet et al., 2003; 
Jackson-Grusby et al., 2001). However, there is an interesting report that shows by 
Southern blotting that the Oct4 gene continues to be highly methylated in Dnmt1 
knockout proliferating fibroblasts, despite the fact that many other genes become 
demethylated (Feldman et al., 2006). This result is presumably because of the 
recruitment of de novo methyltransferases to the Oct4 promoter (Feldman et al., 2006). 
Consistent with this observation, the reactivation of Oct4 and probably its demethylation 
occur at a very late stage of reprogramming (Brambrink et al., 2008; Polo et al., 2012; 
Stadtfeld et al., 2008) Having a sense that one of the main pluripotency genes, Oct4, is 
the epigenetic barrier in iPSC reprogramming, it will be interesting to investigate how 
much DNA methylation in the Oct4 promoter or enhancer region is removed depending 
on the amount of Dnmt1 expression in our allelic series of Dnmt1 MEFs.   
To understand the methylation dynamics at the regulatory regions of the Oct4 
locus, we examined the epigenetic state of known regulatory elements at and around the 
Oct4 promoter. Two regions were selected, covering six CpG dinucleotides near the 3‘ 
end of the proximal enhancer (PE) (Yeom et al., 1996) and 10 CpGs in the proximal 
promoter (PP), respectively (Figure 3.2a). DNA methylation at these regulatory regions 
was determined by bisulfate sequencing in the allelic series of Dnmt1 MEFs. DNA 
methylation levels were reduced at both regions in Dnmt1
chip/1lox MEFs, exhibiting a near 
50% decrease in methylation at the 3‘PE, compared to the wild-type control (Figures 
3.2b-c). Overall, a reduction in DNA methylation levels at these regulatory regions  
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Figure 3.2. Reduced Dnmt1 levels decreased the methylation level of endogenous Oct4 
regulatory regions.  
 
 
a, Sequence of Oct4 promoter and enhancer regions. DNA methylation analysis is focused on 
major regulatory regions including Oct4 proximal promoter (PP) and 3‘ proximal enhancer (3‘ 
PE) regions. b, DNA methylation analysis for Oct4 regulatory regions. Empty circles indicate 
unmethylated and filled circles methylated CpG dinucleotides. c, Quantification of DNA 
methylation analysis. The hypomorphic Dnmt1 MEFs highly demethylated in both 3‘PE and PP 
region as compared to wild-type control.  
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appears to track with the reduced levels of DNMT1 enzyme produced by the different 
Dnmt1 expression levels contributes to a corresponding decrease in DNA hypomorphic 
MEFs (Figure 3.2c). These findings suggest a decrease in endogenous methylation at 
Oct4 locus, which may affect the efficiency of reprogramming in these hypomorphic 
Dnmt1 lines.  
 
Hypomrophic Dnmt1 Enhances the Kinetics and Efficiency of Reprogramming 
To see whether hypomorphic Dnmt1
chip/1lox MEFs that are the most 
hypomethylated in the Oct4 regions can be reprogrammed the fastest and best compared 
to wild-type control or other cell lines expressing various Dnmt1 levels, we transduced 
Dnmt1
+/+, Dnmt1
+/chip, Dnmt1
+/1lox, and Dnmt1
chip/1lox; Oct4::GFP reporter MEFs with 
four reprogramming factors, Klf4, Sox2, Oct4, and cMyc and then sorted the number of 
GFP expressing cells by fluorescent activated cell sorting (FACS). To investigate the 
kinetics of reprogramming from each cell line, we performed FACS from 6 days to 24 
days of reprogramming. Interestingly, we found that the 10%-reduced dosage of Dnmt1 
MEF line, Dnmt1
chip/1lox, was not only the fastest but also the most efficient facilitator of 
iPSC reprogramming (Figures 3.3a-b). We discovered that the less the DNMT1 protein 
level was expressed, the more iPSCs were produced. The 90% reduction in Dnmt1 level 
increases the efficiency of reprogramming over 4-fold as compared to the 100%  
Dnmt1 expressing wild-type control (Figures 3.3a-b). Also, we found that the 
Dnmt1
+/chip line reprogrammed much faster and more efficiently than the Dnmt1
+/1lox line 
(Figures 3.3a-b), indicating that the lower protein level of Dnmt1 in Dnmt1
+/chip line than  
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Figure 3.3. Dnmt1 hypomethylation promotes the efficiency of MEF reprogramming.  
a, Dynamics of the allelic series of Dnmt1 MEFs iPSC reprogramming. The allelic series of 
MEFs infected with Oct4, Sox2, Klf4, and cMyc were sorted for GFP by using FACS from early 
(day 6) to late days (day 24) of the reprogramming process. Dnmt1
chip/1lox line reprogrammed 
with fastest kinetics and highest efficiency. b, FACS analysis, which represent the percentage of 
Oct4::GFP+ cells from each allelic series of Dnmt1 lines at 24 days of iPSC reprogramming. c, 
NANOG+/Oct4+ iPSC line generated from the allelic series of Dnmt1 MEFs using Oct4, Sox2, 
Klf4, and cMyc, scale bars = 100 μm. For all experiments, error bars represent the standard 
deviation between three biological replicates and statistical significance was determined using a 
two-tailed homoscedastic Student‘s t-test. 
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Figure 3.3. (Continued) 
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that in Dnmt1
+/1lox line aids in iPSC generation. These results suggest that decreased 
Dnmt1 levels can significantly enhance the speed and the efficiency of reprogramming.  
In addition, to confirm whether another stringent pluripotency marker, Nanog, is 
activated in our Oct4-GFP positive cells (Silva et al., 2009), we immunostained with the 
Nanog antibody in each of Oct4 positive reprogrammed cell lines sorted by FACS at 24 
days of iPSC reprogramming. We observed that Oct4 positive cells were also Nanog 
positive, indicating that these sorted cells were iPSCs and were fully reprogrammed at 
day 24 (Figure 3.3c). 
 
Dnmt1
chip Allele Transduced Lines Reprogram to Pluripotency by Directly Activating 
Oct4 and Bypassing the Intermediate States. 
To explore the mechanism by which the hypomorphic Dnmt1
chip/1lox MEFs 
reprogrammed faster and more efficiently than other cell lines phenotypically, we first 
hypothesized that the majority of the hypomorphic cell lines are not trapped in the 
intermediate states that are usually present during the iPSC conversion process in wild-
type MEFs, leading to a low efficiency of reprogramming. The activation of stage-
specific embryonic antigen-1 (SSEA-1) represents an intermediate step during iPSC 
reprogramming that precedes the sequential activation of Oct4 and Nanog (Brambrink et 
al., 2008). Therefore, we can capture reprogramming intermediates by FACS using the 
marker of SSEA-1 during early iPSC reprogramming process. To validate reducing 
DNMT1 protein levels generates less intermediates, we first tested with wild-type MEFs, 
if SSEA-1 positive intermediate populations were indeed enriched for cells that would  
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form iPSCs. We sorted cells on feeders based on SSEA-1 and Oct4-GFP expression 
from 6 days to 24 days of reprogramming. Consistent with the previous report (Polo et 
al., 2012), intermediate cells with the potential to give rise to iPSCs were initially 
present as a SSEA-1 positive populations, then progressed to Oct4 positive cells, and 
ultimately transited to the SSEA-1 and Oct4-GFP double positive population (Figure 
3.4a).  
To verify our hypothesis, we next reprogrammed the allelic series of Dnmt1 
MEFs with four reprogramming factors and sorted these reprogramming cells based on 
SSEA-1 and Oct4 expressions at day 6, 9, 12, 17, 24 and passage five established iPSC 
lines from each allelic series of Dnmt1 MEFs. Surprisingly, the hypomorphic 
Dnmt1
chip/1lox line did not significantly expressed SSEA-1 throughout the entire 
reprogramming process, but instead it directly activated Oct4 expression (Figure 3.4a-c). 
Obviously, the Dnmt1
+/chip line behaves differently from wild-type or the Dnmt1
+/1lox line, 
which expresses normal protein levels of DNMT1. Although the Dnmt1
+/chip line 
expressed slightly higher levels of SSEA-1 at later time points of reprogramming (24 
days) than the Dnmt1
chip/1lox line, it did not activate significant level of SSEA-1, 
compared to wild-type control or the Dnmt1
+/1lox line but expressed relatively low levels 
of SSEA-1, similar to Dnmt1
chip/1lox line throughout the reprogramming process (Figure 
3.4a-b).We discovered that both Dnmt1
chip alleles introduced cell lines generated less 
intermediate cells during reprogramming, resulting in fast and efficient iPSC generation. 
Thus, we concluded that the more we reduced the level of DNMT1 in MEFs, the faster 
and more efficient the dynamics of iPSCs production.  
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Figure 3.4. Dnmt1
chip allele transduced line reprograms to pluripotency by bypassing the 
intermediate states.  
a, FACS analysis of reprogrammable allelic series of Dnmt1 MEFs for SSEA-1 and Oct4 at 
indicated time points (at day 6, 9, 12, 17, and 24 of reprogramming and in established iPSC 
lines). Each distribution is indicated in (a) SSEA-1 positive/Oct4 negative, (b) Oct4 
positive/SSEA-1 negative, and (c) SSEA-1 positive/Oct4 positive. b, Quantification from FACS 
analysis. Percentage representations of SSEA-1 positive/Oct4 negative cell populations at day 6, 
9, 12, 17, and 24 of reprogramming. Percentage of SSEA-1 positive/Oct4 negative cells in 
Dnmt1
chip/1lox line (red bars) is extremely low throughout the reprogramming process as 
compared to wild-type control (black bars) or Dnmt1
+/1lox cell line (green bars). c, Quantification 
from FACS analysis. Percentage representations of Oct4 positive/SSEA-1 negative cell 
populations during reprogramming. d, Quantification from FACS analysis. Percentage 
representations of SSEA-1 positive/Oct4 positive cell populations at indicated time points. For 
all experiments, error bars represent the standard deviation between three biological replicates in 
three individual experiments, and statistical significance was determined using a two-tailed 
homoscedastic Student‘s t-test. 
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Figure 3.4 (Continue). 
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Figure 3.4 (Continue).  
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Synergism of DNA Demethylation and Histone Acetylation in Combination with 
Histone Demethylation Promotes the Efficiency of Reprogramming  
High levels of histone acetylation generally correlate with transcriptional activity. 
Because methylation of DNA recruits histone deacetylases via binding of methylated 
DNA binding proteins (Csankovszki et al., 2001), it is possible that DNA demethylation 
and histone acetylation synergistically affect the rate of iPSC reprogramming. To 
demonstrate how histone acetylation can contribute to iPSC reprogramming 
synergistically with DNA demethylation, we transduced the allelic series of Dnmt1 
Oct4::GFP reporter MEFs with the four iPSC reprogramming factors and treated them 
with an inhibitor of histone deacetylase, Valproic acid (VPA) for 7 days (Huangfu et al, 
2008). At 9 days of reprogramming when the VPA treatment was finished, we collected 
and sorted each cell line for Oct4-GFP positive signal. Consistant to the literature, the 
addition of 500µM VPA led to a significant increase in the number of resulting GFP 
positive iPSCs especially for hypomorphic Dnmt1
chip/1lox line as well as other cell lines 
including Dnmt1
+/chip and Dnmt1
+/1lox line (Figure 3.5a). Strickingly, we found that VPA 
treatment in Dnmt1
+/chip line generated over 10-fold more GFP positive cells than the 
VPA-untreated cell line (Figure 3.5a), indicating that a moderate amount of DNA 
demethylation can strongly accelerate cells to reach pluripotency by the assistance of an 
inhibitor of histone deacetylase. These results suggest that histone acethylation can 
positively synergize with DNA demethylation, thereby generating iPSCs more 
efficiently (Figure 3.5a). 
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Figure 3.5. The synergism of DNA demethylation and histone acetylation in combination 
with histone demethylation promotes the efficiency of reprogramming. 
a, Percentage of Oct4::GFP positive cell population in response to VPA quantified by FACS 
analysis in the allelic series of reprogrammable cells. The allelic series of Dnmt1 MEFs were 
treated with 500µM VPA for first 7 days after viral Sox2, Oct4, Klf4 and cMyc infections, and 
then FACS analysis is performed at day 9. b, Percentage of Oct4::GFP positive cell population 
in response to Vitamin C quantified by FACS analysis in the allelic series of reprogrammable 
cells. 50µg/ml Vitamin C was treated on the four factor infected cells for 7 days, and then FACS 
analysis is performed at day 9. c, Percentage of Oct4::GFP positive cell population in response 
to VPA and Vitamin C cocktail quantified by FACS analysis in the allelic series of 
reprogrammable cells. Combination of VPA and vitamin C increases the efficiency of 
reprogramming the most. d, Summary of FACS analysis for Oct4::GFP positive in response to 
VPA and/or Vitamin C in each cell line. e, P0 mouse iPSC colonies generated from Dnmt1
+/1lox 
treated with vitamin C and vitamin C+VPA, respectively, scale bar = 100 µm. For all 
experiments, error bars represent the standard deviation between three biological replicates in 
three individual experiments, and statistical significance was determined using a two-tailed 
homoscedastic Student‘s t-test. 
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Figure 3.5 (Continued). 
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A recent report has shown that histone demethylases enhance somatic cell 
reprogramming in a vitamin-C-dependent manner (Esteban et al., 2010; Wang et al., 
2011). To see whether histone demethylation via vitamin C can synergistically influence 
the rate of cell conversion process to iPSCs, we added vitamin C to the allelic series of 
Dnmt1 cell lines throughout the reprogramming process and sorted Oct4-GFP positive 
iPSCs by using FACS. Consistant to the literature (Esteban et al., 2010), we could 
observe that vitamin C accounted for an over 10-fold increased efficiency in 
reprogramming of wild-type MEFs. Vitamin C significantly enhanced the overall 
efficiency of reprogramming in all of the allelic series of Dnmt1 MEFs (Figure 3.5b). 
When compared to non-treated wild type control, vitamin C-treated hypomorphic 
Dnmt1
chip/1lox line boosted the efficiency of reprogramming over 80-fold in addition to 
the increase (30-fold) by the effect of DNA demethylation (Figure 3.5b). Moreover, we 
also found that vitamin C combined with VPA offered a better synergistic effect in iPSC 
reprogramming. It increased the frequency of reprogramming over 100-fold in both 
compound treated hypomorphic Dnmt1
chip/1lox line than in untreated wild-type control 
(Figures 3.5d). Therefore, we concluded that inhibition of histone deacetylation and 
histon demethylation support DNA demethylation, making it easier to overcome 
roadblocks for iPSC generation that leads to efficient reprogramming.  
 
Reducing Dnmt1 does not Induce Endogenous Oct4 and Nanog Expressions  
One possible mechanism by which the reduction of Dnmt1 enhances iPSC 
reprogramming is through the induction of pluripotency gene expressions. To validate   
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the mechanism that the decreased level of Dnmt1 can highly contribute to facilitate iPSC 
generation by directly activating their endogenous pluripotency loci, we investigated if 
any of allelic series of Dnmt1 MEFs can activate endogenous Oct4 and Nanog 
expressions by RT-qPCR. However, both Oct4 and Nanog expressions in Dnmt1
+/1lox 
and Dnmt1
chip/1lox MEFs were not increased compared to those of wild-type control and 
were much lower than those of mouse ESC control (data not shown), indicating that 
Dnmt1 was not significantly involved in activation of endogenous Oct4 and Nanog gene 
expressions (Figures 3.6a-b).  
 
Hypomorphic Dnmt1
chip/1lox MEF lines have Higher Variations than Other Lines in 
Reprogramming  
To confirm whether individual cell lines which have the same genotype have a 
similar reprogramming potential to pluripotency, we generated three biological 
replicates of MEF lines from three separate embryos, wild-type Dnmt1, Dnmt1
+/chip, 
Dnmt1
+/1lox, and Dnmt1
chip/1lox, respectively. The cell lines were transduced with Klf4, 
Sox2, Oct4, and cMyc, and Oct4-GFP positive cells were sorted from 6 to 24 days of 
reprogramming. Interestingly, hypomorphic Dnmt1
chip/1lox MEF lines are more variable 
than other cell lines in efficiency of reprogramming. Theis data indicate that 
hypomorphic cell lines are unstable in in vitro cell culture systems (Figure 3.3a, black 
line and 3.5a, grey bars).  
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Figure 3.6. Reducing Dnmt1 does not induce endogenous Oct4 and Nanog expression.  
 
 
a-b, QPCR analysis of endogenous a, Oct4 and b, Nanog on the allelic series of Dnmt1 MEFs. 
For all experiments, error bars represent the standard deviation between three biological 
replicates in three individual experiments, and statistical significance was determined using a 
two-tailed homoscedastic Student‘s t-test.  
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Discussion 
In summary, our findings suggest that DNA methylation is a significant 
impediment to the reprogramming of MEFs to iPSCs. We investigated how 
quantitatively modulated Dnmt1 levels can contribute to the efficient iPSC 
reprogramming by generating a transgenic allelic series of Dnmt1 MEFs that sensitively 
regulate the levels of Dnmt1 and by performing FACS analysis with them. We 
discovered that the sequentially decreasing DNMT1 protein expression generates more 
iPSCs. Importantly, the 10%-reduced hypomorphic Dnmt1
chip/1lox line promotes the rate 
and efficiency of reprogramming the most compared to wild-type controls, suggesting 
that highly reduced level of Dnmt1 lowers the kinetic barrier of iPSC reprogramming, 
thereby facilitating the transition to pluripotency. Consistent with our hypothesis, 
lowering the level of DNMT1 protein expression allows the reprogramming cells to 
bypass the intermediate state and directly reach the pluripotent state by activating the 
Oct4 gene. Furthermore, DNA demethylation can synergize with histone acethylation 
and histon demethylation, which is conferred by VPA and vitamin C, respectively, to 
bolstered the rate of iPSC generation. Therefore, we conclude that reducing Dnmt1 
levels removes a critical roadblock of iPSC reprogramming, presumably because the 
decreased Dnmt1 levels induces global DNA hypomethylations that could easily activate 
pluripotency genes (Gaudet et al., 2003). Additionally, histone modifications aid in 
DNA demethylation to demolish the epigenetic barrier of reprogramming. 
In this study, we examined the DNA methylation status of ESC marker gene 
such as Oct4 in all allelic series of Dnmt1 MEFs. The promoter and enhancer regions of  
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Oct4 had lower methylation levels in Dnmt1 modulated cell lines, compared to wild-
type control. Our results suggest that DNA hypomethylation of Oct4 in the hypomorphic 
Dnmt1 cell line might contribute to facilitate the rate-limiting step of iPSC generation. 
Further chromatin immunoprecipitation (ChIP)-qPCR analysis to probe the binding of 
Oct4 along a genomic region of Nanog in the early stage of reprogramming Dnmt1 cell 
lines could explain how Oct4 DNA binding patterns change as their relative Dnmt1 
levels are gradually decreased in the allelic series of Dnmt1 MEFs. By reduced 
representation bisulfate sequencing, a recently developed bisulfate-based approach that 
enriches for genomic regions that contain CpG dinucleotides, thereby reducing the 
amount of sequencing required for the whole genome assay while capturing the majority 
of CpG islands and promoters (Meissner et al., 2005), we could analyze and compare 
differential genomic methylation patterns of somatic genes and pluripotency genes other 
than Oct4 in the allelic series of Dnmt1 MEFs. These investigations will provide a clear 
view of the mechanism by which hypomorphic Dnmt1alleles promote reprogramming. 
There is still unsolved issue that the Dnmt1
+/chip line, which is theoretically 
60%reduced levels of the Dnmt1gene expression, does not express the expected amount 
of DNMT1 protein but expresses highly reduced levels (40%) of DNMT1. It is unclear 
how the hypomorphic allele Dnmt1
chip, which enhances reprogramming efficiency, 
affects epigenetic changes in the genome. Therefore, we expect that further 
characterization of Dnmt1
chip gene transduced cell lines by whole genome sequencing 
will offer critical insights about how DNA demethylation occurred by the hypomorphic  
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Dnmt1
chip allele, and how genome-wide changes of DNA demethylation help facilitate 
the desired transitions, making reprogramming efficient.  
To introduce DNA demethylation into cells, infections with siRNAs or shRNAs 
against DNA methyltrasferase or blunt treatments with compound DNA 
methyltransferase inhibitors have commonly been executed. However, they either cause 
a majority of cell death or induce nonspecific effects. Our study with sensitively 
modulated Dnmt1 cell lines provides an accurate functional control of DNA 
methyltransferase. Also, this precise control of Dnmt1 offers an advanced mechanistic 
insight into how regulated DNA methyltransferase1 can confer demethylation in DNA 
and contributes to promote reprogramming. Our findings could provide a foothold to 
explore the mechanism leading to DNA demethylation in iPSC reprogramming.  
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Materials and Methods 
Derivation of MEFs, Cell Culture, and Genotyping 
The allelic series of MEFs were generated using Dnmt1
2lox/2lox and Dnmt1
chip/chip 
mice (Gaudet et al., 2003; Jackson-Grusby et al., 2001). Primary MEFs were isolated at 
13.5 days post coitum by decapitation and evisceration of embryos. Only embryos, 
which were Oct::GFP transgene germ-line transmitted in gonad, were selected. 
Individual carcasses were minced, trypsinized briefly, then disrupted by extensive 
pipeting. MEFs were cultured in 10% FBS in DMEM medium DNA was extracted from 
passage 2 MEFs and used for PCR genotyping. The following primer sets were used to 
distinguish each allelic series of MEFs: Primers for the Dnmt1 5´ lox site amplify a 334-
bp fragment from the wild-type allele and a 368-bp fragment from the Dnmt1
2lox allele, 
respectively. The reverse primer (R2) was added to the previous primer set to distinguish 
Dnmt1
1lox allele, which amplify a 280-bp fragment. Primers for Dnmt1 chip gene that 
were designed to detect ampicillin resistent site of Dnmt1 cDNA amplify a 200-bp 
fragment. Oct4::GFP reporter transgene were amplified by the primer sets at 173bp. All 
animal research was performed under the oversight of the Office of Animal Resources at 
Harvard University. 
 
Retroviral Infection 
For reprogramming experiments, MEFs in passage 2 were infected by retrovirus 
of four iPS reprogramming factors as previously described using the pMXs vector 
(Takahashi et al., 2007). MEFs were infected once with concentrated viruses for 20  
 
111 
 
hours in 10% FBS in DMEM medium, and reprogramming is performed in knockout 
serum replacement mouse ES medium. The first day that viruses were added was termed 
―day 1 postinfection.‖ For quantification, Oct4::GFP+ colonies were counted at day 15 
postinfection unless otherwise stated.  
 
Flow Cytometry and Immunofluorescence 
For flow cytometry, harvested cells were incubated with antibodies against 
SSEA-1 (AlexaFluor647, MC-480, BioLegend) for 20 min. Cells were washed in PBS 
and then incubated for 30 min. The cells were washed twice in PBS, resuspended in 5% 
FBS/PBS solution and passed through a 40mm cell strainer to achieve single-cell 
suspension. Cells were sorted on a FACSAristo (BD Biosciences), Influx cell sorter 
instrument (BD Biosciences) and/or analyzed in a LSRII (BD Bioscience). All data are 
synchronized and reanalyzed at Kaluza (Beckman coulter). 
 
Generation of iPS Cells 
A P0 colony is generated by FACS for SSEA-1 and GFP double positive cells at 
24 days of reprogramming and plated on a feeder layer in mES cell media. When a 
colony grew bigger, it was incubated in in .25% trypsin (Gibco) for 5 minutes at room 
temperature before plating on a feeder layer in mES cell media. This process was 
repeated until passage 5, at which time colonies were trypsinized and passaged in bulk 
and maintained on feeders in mES cell media. 
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Antibody Staininig for Nanog 
iPS cells were cultured on irradiated MEF feeders in 4 well plates, fixed with 4% 
paraformaldehyde (PFA) and stained with primary antibodies against mNanog 
(RCAB001P, ReproCell), followed by staining with the appropriate secondary 
antibodies conjugated to Alexa Fluor 546 (Invitrogen). Nuclei were counterstained with 
Hoechst33342 (Sigma). 
 
 
Western Blots 
An anti-Dnmt1 antibody generated in chickens to a carboxy-terminal peptide 
from mouse Dnmt1 has been described
53. Passage 2 MEFs were lysed directly in RIPA 
buffer (Invitrogen) containing protease inhibitors. We detected the Dnmt1 antibody 
using an anti-chicken IgY-HRP conjugate (Promega) followed by ECL detection 
(Amersham). 
 
RT-qPCR 
RNA was harvested with Trizol (Invitrogen) and purified by RNeasy mini kit 
(Qiagen) and treated with RNase-free Dnase set (Qiagen) to remove DNA contamination. 
RNA was reverse transcribed using iScript
TMcDNA synthesis kit (Bio-rad). To analyze 
Dnmt1 expression two sets of primer sequences that amplify exon 4 and exon 12-14 of 
endogenous Dnmt1 gene, respectively, were used. SYBR green (Bio-rad) was used for 
QPCR analysis.  
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Methylation Analyses 
Bisulfite conversion of genomic DNA was performed using the Qiagen EpiTect 
kit according to manufacturer‘s instructions. Bisulfite converted DNA was amplified 
with primers covering the Oct4 proximal promoter (PP) and the downstream end of 
proximal enhancer (3‘ PE). PCR reactions were performed with MangoTaq DNA 
Polymerase (Bioline). Cycling conditions were as follows: 2 minutes at 94°C, followed 
by 34 cycles of denaturation at 94°C for 45 seconds, annealing at 59°C (PP) or 55°C (3‘ 
PE) for 35 seconds, and extension at 72°C for 30 seconds, followed by a final extension 
at 72°C for 5 minutes. PCR products were cloned into pCR™II-TOPO
® (Invitrogen) and 
~10 clones sequenced per amplicon.  
 
Chromatin Immunoprecipitation and QPCR 
Between 5 to 10 × 10
6 cells per single immunoprecipitation were collected, 
washed with ice-cold PBS, and fixed with 1% formaldehyde. Cross-linked samples were 
sonicated with a Branson 250 Digital sonifier. Samples were incubated at 4°C overnight 
with 1 ug/10
6 cells Oct-3/4 antibody (sc-8628, Santa Cruz). Complexes were 
precipitated with Protein G Dynabeads (Invitrogen). Beads were washed with low salt 
immune complex wash, high salt immune complex wash, LiCl immune complex wash, 
and TE. Chromatin was eluted in elution buffer, and incubated at 65°C overnight with 
reverse-crosslinking salt mixture. DNA was purified by standard phenol-chloroform 
extraction followed by ethanol precipitation.  Quantitative PCR reactions were 
performed using SYBR
® Green PCR mix (Applied Biosystems) on an Applied  
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Biosystems StepOne Plus Real-Time PCR Systems instrument. Fold enrichment was 
determined by comparing 0.5 ng ChIP-enriched DNA to 0.5 ng whole-cell extract 
unenriched DNA template.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
115 
 
List of Primers: 
 
Dnmt1_1lox 
F 5‘ GGGCCAGTTGTGTGACTTGG 
R1 5‘ CTTGGGCCTGGATCTTGGGGA 
R2 5‘ ATGCATAGGAACAGATGTGTGC 
Dnmt1_chip  F 5‘ GCTATGTGGCGCGGTATTAT 
R 5‘ AAGTTGGCCGCAGTGTTATC 
Oct4::GFP transgene  F 5‘ AAGTTCATCTGCACCACCG 
R 5‘ TCCTTGAAGAAGATGGTGCG 
Dnmt1_cDNA_exon4 
F 5‘ GGAAGGCTACCTGGCTAAAGTCAAG 
R 5‘ ACTGAAAGGGTGTCACTGTCCGAC 
Dnmt1_cDNA_exon12-
14 
F 5‘ GAGGGAGGAGAAGAGACGAAA 
R 5‘ CGGGATCACACTTTTGCTTT 
PP   F 5‘ ATTTAAGGTAGGGGTGAGAGGATTT 
R 5‘ AAATCTAAAACCAAATATCCAACCA 
 3‘ PE 
F 5‘ GATATGGGTTGAAATATTGGGTTTAT 
R 5‘ AATCCTCTCACCCCTACCTTAAAT 
Fgf4_control 
F 5‘ TCACAGAGTCAGGGATGCAC 
R 5‘ AGCAGGGGATCTAGGGAACC 
Fgf4_OctBinding  F 5‘ TCTCCAGGTGACAGTAGCCA 
R 5‘ GACTATCCCGCCACCGTTG 
Oct4_control 
F 5‘ TGACTCTTAAAGGGGGCAGA 
R 5‘ TTTCTAAGACCCAGGAGGCA 
Oct4_OctBinding1 
F 5‘ GAGTTCTTTCCCAGCCCCTA 
R 5‘ ACCTTTTCATGCTGGTGGAC 
Oct4_OctBinding2  F 5‘ TGAACTGTGGTGGAGAGTGC 
R 5‘ CAGAGAAGATGGTTGGGGAG 
Oct4_OctBinding3 
F 5‘ TTGAAAATGAAGGCCTCCTG 
R 5‘ CAAGGCTAGAGGGTGGGATT 
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Chapter 4 
 
Conclusions and Promises of Reprogramming Technology 
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Abstract 
 
Since the birth of induced pluripotent stem cells (iPSCs), rapid progress has been 
made in dissecting molecular mechanism of defined-factor reprogramming as well as 
improving the technology. We have controlled genetic and epigenetic functions that are 
extensively studied in cancer. We have directly modulated Notch signaling pathway, 
which is the developmental signal of keratinocytes with small molecule signal inhibitors, 
offering a critical advance in the field of iPSC reprogramming by preserving tumor 
suppressor activity. In addition, we have generated and reprogrammed with unique cell 
types that are modulated in the expression of DNMT1, rendering interesting insights for 
inducing the process of iPSC generation. Using these cell lines as a platform, we can 
deeply study the molecular mechanism of reprogramming and identify completely 
chemically defined reprogramming cocktails. Furthermore, transdifferentiation on these 
cell types may provide multiple routes for producing a desired cell type and improve the 
efficiency of reprogramming. These new designs could propel these cell conversion 
technologies forward into therapeutic relevance.  
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Insights from Keratinocyte reprogramming      
Combined Chemical and Keratinocyte Developmental Signal Modulation 
We have explored two approaches toward identifying conditions that can replace 
viral transduction of transcription factors and promote the efficiency of reprogramming. 
In one, we used small molecules that modulate specific signal transduction pathways of 
keratinocytes. In the other, we have found that keratinocytes can be reprogrammed with 
fewer genetic manipulations than previously reported for other somatic cell types.  
Various small molecules that have been identified through chemical screening 
can provide information of their functions in cell signaling (Ichida et al., 2009; Li et al., 
2009; Lin et al., 2009), however the precise molecular mechanisms governing iPSC 
reprogramming are still poorly understood. Our new approach is to directly modulate 
developmental Notch signals that are highly conserved in the proliferating and 
differentiating cell type by using a well-known compound inhibitor of Notch signaling, 
named DAPT. It provided a new insight for understanding the precise molecular events 
of iPSC generation and new strategies for expanding the translational utility of lineage 
conversion. 
Since Notch signaling is extensively studied with keratinocytes that highly 
express Notch, we focused our efforts on investigating keratinocyte biology to find a 
way to control its signaling and convert the cells to the pluripotent state. Notch signaling 
is known to negatively regulate keratinocyte stem cell (KSC) potential and induce 
keratinocyte differentiation, by antagonizing p63 expression (Dotto, 2008). Consistently, 
Notch1 and p21WAF1/Cip1, a ‗canonical‘ Notch target in keratinocytes, both suppress  
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Wnt ligand expression and signaling that also limits stem cell potential (Dotto, 2008). 
Based on Notch function in keratinocyte differentiation, we hypothesized blocking 
Notch could induce a less differentiated state in keratinocytes which may increase 
reprogramming potential and reduce reprogramming factors. A detailed discussion of 
our findings about unique molecular mechanism of iPSC generation by Notch inhibition 
will be handled in the following subtopic. 
In the end, the inhibition of Notch by DAPT both in mouse and human 
keratinocytes converts these somatic cells into iPSCs with reduced reprogramming 
factors, only requiring Sox2 and Oct4. We found that Notch inhibition promotes 
keratinocyte reprogramming by enhancing long-term proliferation, which implicates the 
activation of self-renewal. However, more stringent assays are further required to 
address the question of whether a progenitor population that is prolonged and maintains 
its self-renewal activity by DAPT treatment is the real cell target which promotes 
reprogramming. We can sort progenitors and terminally differentiated populations using 
different cell surface antibodies by FACS (Li et al., 2007) and then reprogram each 
population to identify which populations can recapitulate keratinocyte reprogramming to 
pluripotency by Notch inhibition.  
Another interesting finding is that a compound inhibitor of Dot1L synergizes 
with DAPT to enhance the efficiency of reprogramming in Sox2 and Oct4-transduced 
keratinocytes. This finding suggests that a chromatin modifying compound, in this case, 
an inhibitor of the histone methyltransferase could add to the effect of inhibiting 
differentiation to promote reprogramming in keratinocytes.  
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Our efforts to control normal developmental signals to understand the molecular 
mechanism of chemical-mediated reprogramming have revealed interactions between 
signaling pathways during the reprogramming process. Furthermore, our findings with 
Notch demonstrate that developmental signaling pathways can substantially modulate 
the activities of reprogramming transcription factors and thereby affect the quality and 
quantity of the resulting reprogrammed cells. 
 
Oncogenic Factors and p53 Inhibition Dispensable in iPSC Generation 
It has been shown previously that activation of the p53 induced p21 pathway 
during iPSC reprogramming is one of the most significant blockades to generate iPSCs 
(Banito et al., 2009; Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009; Marión et 
al., 2009; Utikal et al., 2009). Ectopic over-expression of reprogramming transcription 
factors can activate p53, which then induces either up-regulation of p21 or apoptosis, 
thereby perturbing reprogramming (Hong et al., 2009; Kawamura et al., 2009). Silencing 
of p53-p21 pathway genes significantly improves the efficiency of reprogramming. This 
approach became an important pathway to reduce reprogramming factors, because p53 
suppression is necessary to eliminate oncogene Klf4 and cMyc (Kawamura et al., 2009; 
Okita et al., 2009). However, repressing the tumor suppresser gene p53 leads to the 
accumulation of genetic mutation in the resulting iPSCs (Marión et al., 2009). Therefore, 
our approach in modulating keratinocyte signal pathways to achieve pluripotency 
became a solution to leave p53 activity intact.  
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In differentiating keratinocytes, endogenous Notch functions as a direct upstream 
regulator of p21 expression, and the activated Notch causes growth suppression through 
upregulated p21 expression (Okuyama et al., 2004). Therefore, Notch inhibition by 
DAPT treatment following p21 suppression could recover pluripotency from growth 
arrested cells. In this context, it was a key question whether Notch inhibition by DAPT 
is independent from p53 down-regulation. Importantly, we have demonstrated that iPSC 
generation by DAPT in keratinocytes is completely independent from p53 activity as 
well as apoptosis. Consistent with this result, DAPT did not generate iPSCs with DNA 
damage. In addition to preserving tumor suppressor activity, the reduction of the anti-
proliferative responses of p21 by Notch inhibition allowed keratinocytes follow the 
reprogramming trajectory to produce iPSCs. Moreover, without p53 suppression, 
endogenous gene expression systems of keratinocytes still offer the ability to generate 
iPSCs without the oncogenic factors Klf4 and cMyc. 
Based on the reported signaling pathways in the context of keratinocytes, we 
have investigated other possible mechanisms of reprogramming, for example, the Wnt 
pathway. In ESCs, Wnt signaling contributes to the maintenance of pluripotency both in 
mouse and human (Cai et al., 2007; Ogawa et al., 2006; Sato et al., 2004;Singla et al., 
2006). It is also known that Wnt signaling promotes reprogramming of somatic cells to 
pluripotency (Marson et al., 2008). Fibroblast-derived iPSCs have been generated 
without exogenous cMyc, although the efficiency of reprogramming is reduced. 
However, this drop in efficiency can be overcome by Wnt/β-catenin stimulation (Marson 
et al., 2008), due to several possibilities including direct regulation of key endogenous  
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pluripotency factors such as Oct4, Sox2, and Nanog by the Wnt pathway, as suggested 
by genomic studies in ESCs.
 In the context of keratinocytes, Notch and p21 both 
suppress Wnt signaling (Devgan et al., 2005).Thus, we could hypothesize that Wnt up-
regulation controlled by Notch inhibition using DAPT may contribute significantly to 
the generation of iPSCs from keratinocytes. However, the majority of the Wnt gene 
family was down-regulated, when the gene expressions after 1, 2, 4, and 7 days of 
DAPT treated keratnocytes were investigated. Additionally, when Wnt signaling was 
activated by treating the cells with the Glycogen Synthase Kinase 3 (GSK3) inhibitor 
CHIR99021, we did not observe an increase in the rate of iPSC reprogramming. 
Therefore, we concluded that Notch inhibition does not stimulate reprogramming by 
increasing Wnt signaling. 
Taken together, our studies demonstrate that pharmacological inhibition of Notch 
makes it possible to generate iPSCs, rendering KLF4 and cMYC oncogenes dispensable 
while preserving p53 tumor suppressor activity. Importantly, our findings enabled the 
production of oncogene-free iPSCs, which could avoid the mutational load.  
 
 
Insights from Dnmt1 reprogramming 
Improving the Efficiency and Kinetics of iPSC reprogramming 
The four-factor iPSC reprogramming efficiency from MEFs using retroviral 
delivery method is roughly 0.001-1%, which is extremely low (Huangfu et al., 2008a 
and 2008b; Takahashi & Yamanaka, 2006).To complete reprogramming, it required at  
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least15-20 days. Many efforts have been made to improve the reprogramming efficiency 
and kinetics by using different methods and protocols, starting with different somatic 
cell types other than fibroblasts, and treating with chromatin modifying compounds, etc. 
So far the best increase in the efficiency is 4.4% using four factors in modified mRNA 
with VPA when derived from fibroblasts, albeit this process still retains slow kinetics 
(Warren et al., 2010). Therefore, we conclude that the epigenetic barrier to achieve 
pluripotency is quite huge and difficult to overcome. Based on reported reprogramming 
processes, we hypothesized DNA methylation may play a critical role in the blockage of 
reprogramming. 
Our approach of reducing the DNMT1 enzyme, which may lead to DNA 
hypomethylation, increases the efficiency of reprogramming up to six-fold, compared to 
that of wild-type fibroblast reprogramming. More dramatically, reprogramming in 10%-
expressing DNMT1 fibroblasts showed the fastest kinetics by activating the late-
pluripotency marker, Oct4 at early time points of reprogramming; iPSCs from this cell 
line appear the earliest at days 5-6, compared to wild-type iPSCs that appear around 9-
10 days. Strickingly, by introducing chromatin modifying compounds, such as VPA and 
vitamin C, in reduced DNMT1 MEFs, we could increase the efficiency over 100-fold in 
VPA and vitamin C-treated hypomorphic MEFs as compared to untreated wild-type 
control. These results suggest that DNA demethylation dramatically synergizes with 
histone acetylation and histone demethylation, thereby significantly lowering the 
epigenetic barriers of reprogramming. Therefore, our results have shown that lowering 
DNMT1 activity has significant contributions in enhancing reprogramming efficiency  
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and kinetics. Further investigations of how modulated Dnmt1 confers DNA 
demethylation in genome-wide will provide important information for the exact 
molecular mechanism and nature of the difficulties in iPSC reprogramming. 
 
Bypassing Partially Reprogrammed Cell States 
A possible reason for having low efficiency is that the majority of cells during 
reprogramming are trapped and cannot overcome the barrier of reprogramming to 
achieve pluripotency. The intermediate cells appear transiently before converting into 
iPSCs, but the trapped intermediate cells stably propagate and become partially 
reprogrammed cells that have completely different characteristics from iPSCs; in 
partially reprogrammed cell lines, the viral transgenes that are used to deliver 
reprogramming factors are still activated, while pluripotency genes are silent, showing 
incomplete demethylation and reactivation (Mikkelson et al., 2008; Takahashi and 
Yamanaka, 2006). 
Transcription factor-induced reprogramming to pluripotency is a gradual process 
(Brambrink et al., 2008; Polo et al., 2010; Stadtfeld et al., 2008). Based on the analysis 
of the activation timing of known pluripotency markers during iPSC reprogramming, 
alkaline phosphates (AP) was first activated, followed by SSEA-1, and then Oct4 and 
Nanog were observed at later time points of reprogramming in iPSCs that are fully 
reprogrammed (Brambrink et al., 2008). Consistent with this surface marker analysis, 
90-95% cells first lose fibroblast marker Thy1, then progressed to SSEA-1 positive, and 
ultimately a few cells transited to the SSEA-1 and Oct4 double positive, which  
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represents iPSCs (Polo et al., 2010). In their further assay, the majority of trapped Thy1 
negative and SSEA positive cells are considered the trapped intermediate cells during 
reprogramming (Polo et al., 2010). 
To dissect the mechanism of reprogramming, it could be informative to study 
reprogramming intermediates. Hochedlinger and colleagues have examined intermediate 
cell populations poised to becoming iPSCs by genome-wide analyses. To induce 
pluripotency, two transcriptional waves, first the cMyc/Klf4 wave and second the 
Oct4/Sox2/Klf4 wave are necessary. Cells that become refractory to obtain pluripotency 
activate the first wave but fail to initiate the second transcriptional wave. However, only 
a few cells that pass the second wave and are fully reprogrammed finally obtain changes 
in DNA methylation. 
Looking through the mechanism of reprogramming, our reprogramming study 
which modulated the final step of iPSC generation, DNA methylation, brought an 
interesting insight about a roadblock of reprogramming. Our hypomophic Dnmt1 MEFs 
did not follow the sequential expression of pluripotency markers during direct 
reprogramming. MEFs with reduced DNMT1 did not significantly express SSEA-1 
throughout the reprogramming process, suggesting that DNA hypomethylation that may 
be conferred by a low level of Dnmt1 expression bypassed the formation of intermediate 
cells. More importantly, they directly activated Oct4 at the early time point of 
reprogramming, thereby increasing their dynamics.  
Further gene expression analysis with the reprogramming intermediates from our 
allelic series of Dnmt1 MEFs will provide interesting insights of how reduced DNMT1  
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cells pass through a different trajectory from the normal reprogramming process, and 
what is the requiring event to gain pluripotency. This will lead to fundamental advances 
in our understanding of how reduced levels of Dnmt1 expression lower the barrier of 
reprogramming.  
 
 
Broader Implications of Our Findings from the Cancer Research 
The Pleiotropic Functions of Notch in Cancer 
Notch signaling is a highly conserved signaling pathway in multicellular 
organisms. Notch signaling plays a critical role in a wide variety of cellular process, 
including the maintenance of stem cells, the participation in cell-fate decisions, and the 
induction of differentiation and proliferation (Leong and Karsan, 2006). Especially, 
these functions are important in the context of the role of Notch in cancer. The 
interesting features of Notch in tumorigenesis are its dual functions: oncogenic or tumor 
repressive depending on the cellular context. 
The oncogenic role of Notch was first identified in human T-cell neoplasia. 
These cancer cells possess a specific chromosomal translocation that attaches a portion 
of chromosome 7 to chromosome 9, which is characterized by the juxtaposition of the 3‘ 
region of the human NOTCH1 gene into the T-cell-receptor-β (TCRβ) locus, resulting in 
consequent overexpression of the active form of Notch1 (Notch-IC1). Sklar and 
colleagues first identified the fusion of these two loci in a T-cell acute lymphoblastic 
leukaemia (T-ALL) (Reynolds et al., 1987). Mice reconstituted with haematopoietic  
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progenitor cells expressing the human Notch-IC1 proteins develop T-cell leukaemia. 
They generate immature T cells in the bone marrow (Pear et al., 1996) with 
simultaneous inhibition of B-cell development, indicating that NOTCH1 signaling 
drives haematopoietic progenitor cells into the T-cell lineage (Pui et al., 1999).The loss-
of-function experiments in which Notch1 in bone-marrow progenitors was inactivated, 
demonstrated that Notch1 is essential for normal T-cell lineage commitment (Radtke et 
al., 1999). Aberrant Notch-IC1expression in bone-marrow progenitors leads to immature 
T cells. Overtime, these mice develop highly aggressive monoclonal T-cell tumors by 
additional mutations cooperating with the Notch-IC1. This mouse model supported the 
idea that deregulated expression of the cytoplasmic part of the NOTCH1 protein causes 
T-ALL in humans. After the discovery of its involvement in T-ALL, Notch signaling 
was also implicated in various tumors, including breast cancer, medulloblastoma, 
colorectal cancer, non–small cell lung carcinoma (NSCLC), and melanoma 
(Ranganathan et al., 2011), although their extent and causality remained to be verified. 
Although Notch can contribute to the process of tumorigenesis, it needs to 
cooperate with other oncoproteins to actually cause cancer. When expressing Notch-IC1 
with oncoproteins that commonly override the G1-S checkpoint such as adenovirus E1A 
(Capobianco et al, 1997), human papillomavirus (HPV) E6 and E7 (Rangarajan et al., 
2001), RAS (Fitzgerald et al, 2000), MYC (Girard et al, 1996) or simian virus 40 large T 
(SV40T) (Bocchetta et al, 2003) in vitro, transformation can be induced in various cell 
types through various mechanisms. NOTCH-IC1 activates PI3K signaling (Rangarajan 
et al., 2001), which confers resistance to apoptosis (Frisch et al, 1994; Khwaja et al,  
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1997), expresses ERBB2 (Chen et al, 1997), which stimulates proliferation and growth 
of cells, and induces NF-κB2 (Oswald et al, 1998), which activates anti-apoptotic 
proteins (Lin et al, 2003). Therefore, the contribution of Notch to tumorigenesis is 
unlikely to be the abrogation of the checkpoint, but instead, it might provide 
complementing oncogenic features, such as a resistance to apoptosis, or differentiation. 
 In contrast, evidence that components of the same Notch pathway have tumor 
suppressive functions emerged from studies on skin as well as hematopoietic cells, 
pancreatic epithelium, and hepatocytes. Tumor suppressor genes are classically defined 
as genes whose mutation or loss is required for tumor development (Hahn and Weinberg, 
2002). The skin is composed of several layers of keratinocytes that are at various stages 
of differentiation. In normal tissue, proliferating keratinocytes are present mainly in the 
basal layer of the epithelium and become more differentiated by continuously migrating 
to upper layer (Rangarajan et al., 2001). In the skin keratinocytes, the tumor suppressive 
activity of Notch signaling induces cell cycle arrest and differentiation (Lowell et al., 
2000; Rangarajan et al., 2001; Nguyen et al., 2006). Conditional deletion of NOTCH1 in 
keratinocytes results in a significant increase of the basal epidermal layer, largely 
because of a substantial increase in the number of layers of proliferating cells 
(Rangarajan et al., 2001). Consistent with a tumor suppressive function for Notch in 
keratinocytes, NOTCH1 loss of function in mice epithelia develops spontaneous basal 
cell carcinomas over time (Nicolas et al., 2003).   
Various cancers including basal-cell carcinomas are associated with the aberrant 
Sonic-hedgehog (Shh) signaling and the Wnt signaling. In the presence of Notch  
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signaling, little or no Shh and Wnt are expressed in normal mouse and human skin. On 
the contrary, the absence of Notch signaling in mouse or human epidermis results in 
deregulated Shh signaling, which could lead to the development of basal-cell carcinomas 
(Thélu et al., 2002). Notch1-deficient mouse skin reactivates Wnt signaling by the 
increase in β-catenin, which could cooperate with other cellular changes to initiate these 
cancers (Boonchai et al., 2000; Lo Muzio et al., 2002). These studies suggest that Notch 
acts as a tumor suppressor.  
With respect to iPSC reprogramming, it has been recognized that the extent of 
cellular differentiation and proliferative capacity of a given somatic cell are important 
determinants for efficient reprogramming. However, it has not been investigated 
whether forcing a population of differentiated somatic cells into a more potent ―self-
renewing‖ state can increase the reprogramming efficiency. Moreover, the effects of 
modulating Notch signaling on reprogramming have not been studied in any context. We 
have used the tumor suppressing function of Notch as one of the dual functions in 
keratinocytes. By de-repressing growth suppression of Notch using chemicals, we were 
able to modulate the cell fate and efficiently induce them to the pluripotent state. The γ-
secretase inhibitor DAPT or DBZ, which blocks Notch signaling in keratinocytes 
promote iPSC generation from mouse and human keratinocytes. 
To understand the reprogramming mechanism of these γ-secretase inhibitors in 
iPSC reprogramming, we performed microarray analysis on DAPT-treated 
reprogramming keratinocytes and searched for significant changes. We found that Wnt 
signaling genes or Gli2, which is a downstream component of the Shh-signaling were  
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not activated but the anti-proliferative gene p21 was highly decreased by Notch 
inhibition during reprogramming.  Throughout the confirmation of other signaling 
pathways involved in Notch signaling during keratinocyte reprogramming, we 
demonstrated that Notch inhibition by γ-secreatase inhibitors enhances keratinocyte 
reprogramming by inhibiting p21 activity while preserving another known tumor 
suppressor p53 expression. 
Our critical finding that Notch inhibition renders both oncogenic transgenes and 
p53 inhibition dispensable during iPSC reprogramming could provide a safer approach 
for the generation of iPSCs. According to the oncogenic feature of Notch function, 
inhibited Notch signaling itself during reprogramming can prevent its cooperation with 
other oncogenes, Klf4 or cMyc from the reprogramming cocktail, although all four 
factors are present. However, even if the oncogenic function of Notch is reactivated in 
iPSCs, it wouldn‘t be cancerous because oncogenic factors from the four factors were 
omitted by compensating the oncogene expression from the endogenous profile of 
keratinocytes during reprogramming. When considering the tumor suppressor function 
of Notch, our findings still offer a safer source of iPSC generation. Although an initial 
temporal inhibition of Notch is used to induce pluripotency, this would hardly induce 
mutations, regardless of the presence or absence of Notch signaling in the resulting 
keratinocyte-derived iPSCs because Notch is under direct control of tumor suppressor 
p53 in keratinocytes (Lefort et al, 2007; Mandinova et al., 2008). Plus, our finding that 
p53 expression during the reprogramming process is retained regardless of Notch 
inhibition, keeps the tumor suppression function maintaining in the cells.   
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Hypermethylation & Hypomethylation of DNA in Tumor Formation 
In normal cells, almost the entire genome is highly methylated except for CpG 
islands, which are left unmethylated. However, cancer cells are characterized by an 
abnormal pattern of DNA methylation: DNA hypermethylation at CpG islands and DNA 
hypomethylation at most non-CpG island regions (Feinberg et al., 1983; Widschwendter 
et al., 2007). For example, both global DNA hypomethylation and promoter 
hypermethylation of tumor suppressor genes occur in cancer (Issa, 2000; Ohm et al., 
2007). Hypermethylation and hypomethylation of DNA are relative terms and refer to 
―more‖ or ―less‖ methylation compared to DNA from healthy cells.  
The role of aberrant promoter hypermethylation in the inappropriate silencing of 
tumor suppressor genes is well documented (Jones and Baylin, 2002). Many studies 
have confirmed that hypermethylation is predominantly targeted for CpG islands in 
promoters and first exons of some tumor suppressor genes by de novo methylation 
(Herman, 1999; Ohm et al., 2007; Schlesinger et al, 2007; Widschwendter et al., 2007). 
As a consequence, their regulation in cell cycle control, apoptosis, DNA repair, 
differentiation, cell adhesion, angiogenesis inhibition, and metastasis suppression is 
stopped (Esteller et al, 2001 and 2006) .Unlike genetic alterations, which lead to 
immediate disruptions of protein function in tumor, promoter CpG-island 
hypermethylation is a more gradual and progressive process that leads to a gradual 
silencing of tumor suppressors (Graff et al., 2000). This represents the characteristics of 
the heterogeneity of tumor properties. Unlike genetic mutations, epigenetic 
modifications can be reverted. To reactivate these silenced genes, DNA  
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methyltransferase inhibitors such as 5-aza-2'-deoxycytidine have been used successfully 
to treat cancer in humans (Lübbert, 2000). 
In addition to the de novo methylation, tumor cells are also characterized by a 
high degree of global DNA hypomethylation. Global loss of DNA methylation generally 
occurs at centromeric repeats and repetitive sequences in many human cancers. Through 
the investigation of whether this epigenetic change is a cause or consequence of 
tumorigenesis, it is currently thought that DNA hypomethylaiton plays a causal role in 
tumor formation through the enhancement of genomic instability (Ehrlich et al., 2009; 
Gaudet et al., 2003). Hypomethylation of repeated DNA sequences can disrupt the 
functions of neighboring genes through transcriptional interference and activate 
transposable elements that can potentially lead to mutagenesis (Wilson et al., 2007). In 
addition, this phenomenon has been discovered in the premalignant stages of various 
types of human cancers, suggesting that hypomethylation may be an early event in 
carcinogenesis (Ehrlich, 2006). Therefore, global DNA hypomethylation has been used 
recently as a marker of potential cancer risk (Hsiung et al., 2007; Moore et al., 2008). 
In terms of iPSC reprogramming, it has been reported that knockout Dnmt3a and 
Dnmt3b fibroblasts enable reprogramming to pluripotency with a similar efficiency of 
wild type cells, suggesting that de novo DNA methyltransferase3a and 3b are 
dispensable for iPSC generation (Pawlak et al., 2011). However, no one has looked at 
whether knockout Dnmt1 affects iPSC reprogramming, due to the fact that knocking out 
Dnmt1 leads to embryonic lethality (Li et al., 1992) and is not tolerated in somatic 
fibroblasts (Jackson-Grusby et al., 2001), indicating the importance of Dnmt1 in  
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maintaining global DNA methylation patterns for survival of somatic cells. Although it 
is difficult to investigate changes of reprogramming in response to DNA demethylation 
by completely knocking-out Dnmt1, we have created a system that sensitively modulates 
the levels of DNA methylation using the hypomorphic Dnmt1
chip allele and studied iPSC 
reprogramming dynamics and efficiency. However, it is unclear how the Dnmt1
chip allele 
contributes to the genome at the epigenetic levels. 
It has been reported that hypomethylated Dnmt1
chip/- mice, which reduces Dnmt1 
expression to 10% of wild-type levels and results in substantial genome-wide 
hypomethylation in all tissues, developed aggressive T cell lymphomas that displayed a 
high frequency of chromosome 15 trisomy at 4 to 8 months of age (Gaudet et al., 2003). 
Although Dnmt1
chip/- (or Dnmt1
chip/1lox) mice have the runted phenotype, they are fertile 
when they are young. However, Dnmt1
chip/- mice do not breed even with wild-type mice 
and die after 3 months. It is unclear how the hypomorphic allele, Dnmt1
chip, affects the 
epigenetic changes in the genome. Therefore, we can perform whole genome wide 
bisulfate sequencing with 1 month and 3 months-old T cells and sperm to investigate 
genome-wide change of DNA methylation. 
 
 
Potential Opportunities in Reprogramming 
Oct4 Screening on Hypomorphic Dnmt1 Cells toward Identifying Transgene-Free 
Chemical Cocktail  
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Although key advances toward safer delivery methods of iPSC generation have 
been achieved with non-integrating gene delivery methods, recombinant proteins, or 
synthetic mRNAs, a desired approach for the generation of iPSCs with better quality and 
understanding of the molecular mechanism of reprogramming were demanding. One 
potential reprogramming method is using chemicals that may provide improved 
efficiency and specificity in the process of iPSC reprogramming. 
Small molecules have emerged as valuable tools with distinct advantages for 
iPSC generation because small molecules can identify and manipulate biological 
pathways that mediate reprogramming. Such compounds would not only facilitate 
reprogramming but could also be used to characterize the rate-limiting steps (epigenetic 
mechanisms) in the cell conversion process (Xu et al., 2008). For instance, regulating 
protein functions is much easier with small molecules rather than by genetic 
manipulation. Importantly, the effects of small molecules on cells are typically rapid and 
reversible. We can also fine tune by varying concentrations and combinations of small 
molecules that could provide temporal and flexible regulation of complex signaling 
networks. Thus, these characteristics of chemicals could not only offer a chance to 
understand the molecular mechanism governing iPSC reprogramming but also find a 
safer alternative to potentially dangerous viral transgenes. 
A major advance in iPSC reprogramming is that small molecules that can 
functionally replace three of the four viral reprogramming factors (i.e., Sox2, Klf4 and 
cMyc) on MEFs were discovered, thereby enabled the iPSC generation using Oct4 alone. 
Controlling direct epigenetic and signaling mechanisms, researcher could find each  
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transgene replacer, for example, Repsox for Sox2 replacer (Ichida et al., 2009), and VPA 
for Klf4 and cMyc replacers on MEFs (Haungfu et al., 2008b). Eventually, a small 
molecule, a protein arginine methyltransferase inhibitor AMI-5, which enabled 
reprogramming of MEFs with only the Oct4 transgene in combination with the 
transforming growth factor (TGF)-β inhibitor, A-83-01 (Yuan et al., 2011). The small 
molecule inhibitor of G9a histone methyltransferase, BIX-01294, that replaces the Oct4 
transgene in the presence of the other three factors, Sox2, Klf4 and c-Myc, was identified 
in the reprogramming of neural progenitor cells (NPCs), however, in MEFs this 
compound cannot substitute for Oct4, but Sox2 (Shi et al., 2008). Since NPCs are not a 
clinically useful cell source, it is critical to identify a small molecule replacement of 
Oct4 on easily accessible cell types, such as patient fibroblasts towards the final goal of 
a complete chemical cocktail for iPSC generation. 
              To eliminate the Oct4 transgene and achieve complete chemical reprogramming, 
we first screened for an Oct4 replacer in a variety of ways using a chemical library. 
Chemicals are able to replace a transgenic factor either by functionally compensating for 
its absence through other mechanisms or inducing its expression in the somatic genome. 
We have developed a phenotypic chemical complementation screen and high-throughput 
luciferase assay in which to fit both mechanisms (Figure 4.1a-b). The systems were 
applied with a completely annotated chemical library including cell surface receptor 
agonists, kinase inhibitors, channel modulators, inducers of chromatin modeling and 
regulators of stem cell properties. We first performed a phenotypic chemical 
complementation screen for Oct4 replacements by virally transducing Klf4, Sox2, and   
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Figure 4.1. Small molecule screening strategies have been applied in identification of Oct4 
chemical replacements.  
 
 
 
a, phenotypic chemical complementation screen. Oct4::GFP transduced MEFs were virally 
tranduced with Klf4, Sox2 and cMyc, five days later, were plated into 96-well plates. Each well 
was administered once every three days with a single compound from the library in the presence 
of VPA. After 16-30 days, the screen was assayed for GFP positive iPS colonies that had 
emerged after chemical treatments.  b, high-throuput luciferase screen. HEK293T cells were 
transiently transfected with Oct4-luciferease reporter construct, and six hours later, were plated 
into 384-well plate. Each signal well was treated once every 48 hours a single molecule from the 
library. After 96hours, the screen was assayed for compounds that induced high luciferase 
activity. 
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cMyc in Oct4::GFP MEFs in the presence of chromatin modifiers. Secondly, to find 
direct Oct4 chemical inducers, a high-throughput luciferase screen was executed. 
Although a few potential Oct4 replacer candidates found in these screens could increase 
the efficiency of reprogramming under the presence of the Oct4 transgene, none of the 
chemicals could replace Oct4 in the reprogramming assay. Lastly, we hypothesized that 
Klf4, Sox2 and cMyc transduced partially reprogrammed cells (KSM lines) might easily 
convert to iPSCs by certain chemical treatments based on several reports that partially 
reprogrammed cells were able to convert into iPSCs by the treatment of a DNA 
methyltransferase inhibitor, 5-azacytidine (AZA) (Mikkelson et al., 2008) and that the 
small molecule RepSox works during the late stages of reprogramming on intermediate 
cell types which form approximately 10 days after viral transduction (Ichida et al., 2009). 
Based on this notion, a KSM line was screened by phenotypic chemical 
complementation using a selectively sorted compound library. However, the KSM line 
was not responsive to any chemical combination. None of the screening strategy offered 
any potential Oct4 chemical replacement. These results indicate that epigenetic barriers 
to activate pluripotency genes are formidable, therefore, it could be a challenge to re-
activate a pluripotent state by controlling signaling pathways using only chemicals.  
With respect to mechanistic insights of iPSC generation from NPCs by BIX-
01294 that substitutes Oct4, this compound may function to facilitate a shift in the 
epigenetic balance from Oct4 silencing to activate transcription by histone modifications. 
Based on the function of BIX-  
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01294 on NPCs, we can utilize our hyomorphic Dnmt1 MEFs, which already have 
significantly lowered epigenetic barriers by reducing DNMT1 levels, in combination 
with histone modifications as described in previous chapter 3, for the phenotypic screen 
to identify Oct4 replacements. If this works, we can further explore a transgene-free 
chemical cocktail by combining various replacement compounds. These findings render 
a critical insight into the mechanism of iPSC generation. Furthermore, we could apply 
this protocol to patient specific iPSC generation. Finally, iPSC reprogramming by 
chemicals would transit a differentiated cell to a pluripotent state through a completely 
guided direction. 
 
Transdifferentiation on Hypomorphic Dnmt1 Cells 
While nuclear reprogramming has revealed the capacity for a differentiated 
nucleus to be reprogrammed to a pluripotent state, researchers have investigated the 
potential for directly switching from one mature somatic cell type into another mature 
somatic cell of alternate fate without reversing into a pluripotent state. 
To explore this potential, Blau and colleagues performed experiments in which 
human amniocytes were fused to mouse muscle cells, resulting in activation of human 
muscle-specific genes in the heterokaryons within 24 hours (Blau et al., 1983). This 
suggests that the human fibroblast nuclei have adopted a muscle-specific gene 
expression program. The prime candidates for converting cell fates are transcription 
factors, the class of genes that control the expression of other genes.  
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The initial discoveries in this field have compelled others to identify specific 
transcription factors for converting from one somatic cell type to another, named 
transdifferentiation. Taylor and Jones‘s group first discovered that mouse immortalized 
(C3H10T1/2) embryonic fibroblasts which do not contain or form myoblasts (Reznikoff 
et al., 1973) can be readily induced to form functional skeletal myotubes 9 days after the 
low-dose treatment of AZA, an inhibitor of DNA methylation (Constantinides et al., 
1978). This arose from the fusion of mononucleated precursors. In addition, when mouse 
C3H10T1/2 embryonic fibroblasts were exposed with AZA, they could also observe 
spontaneous differentiation into adipocytes and chondrocytes (Taylor and Jones, 1979), 
indicating that DNA methylation restricted gene expression of alternate lineages (Taylor 
and Jones, 1979). Thereafter, Davis, Weintraub and Lassar sought a gene responsible for 
the muscle fate switch in AZA-treated fibroblasts by screening a myoblast cDNA library. 
They reasoned that a small number of powerful muscle inducing genes became de-
repressed due to demethylation of DNA. Strickingly, they found that expression of only 
one transcription factor, MyoD could convert fibroblasts into contracting myoblasts 
(Davis et al., 1987). This is the first discovery of a transcription factor that can function 
outside of its normal cellular context to switch cell lineage. 
Although AZA causes cytotoxicity to the cells, low dosages (0.03-0.3µM) of 
exposure for 24 hours made embryonic fibroblasts convert to myotubes, adipocytes and 
chondrocytes 9-10 days after treatment, when the cells have passed through several 
division cycles in the absence of AZA (Constantinides et al., 1978; Taylor and Jones, 
1979). It will be interesting to first test on our hypomorphic Dnmt1 MEFs with wild-type  
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MEF control and C3H10T1/2 cells as a positive control in the presence or absence of 
AZA to see whether cells that have demethylation of DNA conferred by reduced 
DNMT1 enzyme themselves can easily convert to myoblasts or any other cell types that 
have not been reported, and/or they require AZA treatments to transform to myoblasts. 
Transdifferentiation from different types of embryonic fibroblasts to myoblasts 
by MyoD occurred at various efficiency ranges from 3-50%. For example, 53% of 
transfected C3H10T1/2 colonies were myogenic, whereas 3% of G418 resistant L cells 
(mouse fibroblasts) and 45% of Swiss 3T3 colonies were myogenic (Davis et al., 1987). 
This result indicates that MyoD may operate in a permissive environment such that it 
activates depended on the differentiated state of cells, as if C3H10T1/2 cells are only 
one step away from myogenic determination. Alternatively, it is conceivable that genes 
that are essential for myogenic conversion are stably repressed by DNA methylation in 
certain cell type that has a low efficiency. We could hypothesize that the higher 
frequency of myogenesis in C3H10T1/2 cells is due to less DNA methylation in 
myogenesis-controlling genes than Swiss 3T3 cells. Therefore, it will be exciting to 
explore whether our hypomorphic Dnmt1 cell line can transdifferentiate to myoblasts by 
MyoD transfection at higher efficiency than even C3H10T1/2 embryonic fibroblasts. 
The results will offer insights into the epigenetic barrier, especially DNA methylation, of 
transdifferentiation between cell lines. 
Furthermore, various transdifferentiations from fibroblasts to hepatocyte-like 
cells, cardiomyocytes, induced neuron (iN), and induced motor neuron (iMN) have been 
made using defined factors (Ieda et al., 2010; Haung et al., 2011; Sekiya and Suzuki,  
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2011; Son et al, 2011; Vierbuchen et al., 2010). However, the low efficiency of 
conversion still remained as a challenge. Thus, we can figure out whether other 
transdifferentiations can occur at high frequency by our DNA demethylated cell line, 
delivering a correlation of DNA methylation and lineage barriers.  
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Closing Remarks 
Our findings collectively represent a critical step toward understanding 
molecular mechanism and epigenetic barriers of iPSC reprogramming. It also provides 
insights into how genetic and epigenetic modulators of cancer contribute to iPSC 
derivation. Furthermore, our epigenetically modulated cell line may provide a unique 
platform in the quest of the reprogramming process. It may allow the generation of 
iPSCs in completely chemically defined condition without any genetic modification or 
other cellular conversions efficiently. It is hoped that future application of these types of 
strategies will further improve the understanding of iPSC generation and will eventually 
make an impact in cell therapy for human disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
147 
 
References 
 
Banito, A., Rashid, S.T., Acosta, J.C., Li, S., Pereira, C.F., Geti, I., Pinho, S., Silva, J.C., 
Azuara, V., Walsh, M., Vallier, L., Gil, J. (2009). Senescence impairs successful 
reprogramming to pluripotent stem cells.Genes Dev 23, 2134-2139. 
 
Blau, H.M., Chiu, C.P., Webster, C. (1983). Cytoplasmic activation of human nuclear 
genes in stable heterocaryons. Cell 32, 1171-1180. 
Bocchetta, M., Miele, L., Pass, H.I., Carbone, M. (2003). Notch-1 induction, a novel 
activity of SV40 required for growth of SV40-transformed human mesothelial cells. 
Oncogene 22, 81-89. 
 
Boonchai, W., Walsh, M., Cummings, M., Chenevix-Trench, G. (2000). Expression of 
beta-catenin, a key mediator of the WNT signaling pathway, in basal cell carcinoma. 
Arch Dermatol 136, 937-938. 
 
Brambrink, T., Foreman, R., Welstead, G.G., Lengner, C.J., Wernig, M., Suh, H., 
Jaenisch, R. (2008). Sequential expression of pluripotency markers during direct 
reprogramming of mouse somatic cells. Cell Stem Cell 2, 151-159. 
 
Cai, L., Ye, Z., Zhou, B.Y., Mali, P., Zhou, C., Cheng, L. (2007). Promoting human 
embryonic stem cell renewal or differentiation by modulating Wnt signal and culture 
conditions. Cell Res 17, 62-72. 
 
Capobianco, A.J., Zagouras, P., Blaumueller, C.M., Artavanis-Tsakonas, S., Bishop, J.M. 
(1997). Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and 
NOTCH2. Mol Cell Biol 17, 6265-6273. 
 
Chen, Y., Fischer, W.H., Gill, G.N. (1997). Regulation of the ERBB-2 promoter by 
RBPJkappa and NOTCH. J Biol Chem 272, 14110-14114. 
 
Constantinides, P.G., Taylor, S.M., Jones, P.A. (1978). Phenotypic conversion of 
cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol 66, 57-71. 
 
Davis, R.L., Weintraub, H., Lassar, A.B. (1987). Expression of a single transfected 
cDNA converts fibroblasts to myoblasts. Cell 51, 987-1000. 
 
Devgan, V., Mammucari, C., Millar, S.E., Brisken, C. & Dotto, G.P. (2005). 
p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream 
of Notch1 activation. Genes Dev 19, 1485-1495. 
 
Dotto, G.P. (2008). Notch tumor suppressor function. Oncogene 27, 5115-5123. 
  
 
148 
 
Ehrlich, M. (2009). DNA hypomethylation in cancer cells. Epigenomics 1, 239-259.    
 
Ehrlich, M. (2006). Cancer-linked DNA hypomethylation and its relationship to 
hypermethylation. Curr Top Microbiol Immunol 310, 251-274. 
Esteller, M. (2006). The necessity of a human epigenome project. Carcinogenesis 27, 
1121-1125. 
 
Esteller, M., Corn, P.G., Baylin, S.B., Herman, J.G. (2001). A gene hypermethylation 
profile of human cancer. Cancer Res 61, 3225-3229. 
 
Feinberg, A.P., Vogelstein, B. (1983). Hypomethylation distinguishes genes of some 
human cancers from their normal counterparts. Nature 301, 89-92. 
 
Fitzgerald, K., Harrington, A., Leder, P. (2000). Ras pathway signals are required for 
notch-mediated oncogenesis. Oncogene 19, 4191-4198. 
 
Frisch, S.M., Francis, H. (1994). Disruption of epithelial cell-matrix interactions induces 
apoptosis. J Cell Biol 124, 619-626. 
 
Gaudet, F., Hodgson, J.G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J.W., 
Leonhardt, H., Jaenisch, R. (2003). Induction of tumors in mice by genomic 
hypomethylation. Science 300, 489-492. 
 
Girard, L., Hanna, Z., Beaulieu, N., Hoemann, C.D., Simard, C., Kozak, C.A., Jolicoeur, 
P. (1996). Frequent provirus insertional mutagenesis of Notch1 in thymomas of 
MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for 
oncogenesis. Genes Dev 10, 1930-1944. 
 
Graff, J.R., Gabrielson, E., Fujii, H., Baylin, S.B., Herman, J.G. (2000). Methylation 
patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, 
heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 
275, 2727-2732. 
 
Hahn, W.C., Weinberg, R.A. (2002). Modelling the molecular circuitry of cancer. Nat 
Rev Cancer 2, 331-341. 
 
Herman, J.G. (1999). Hypermethylation of tumor suppressor genes in cancer. Semin 
Cancer Biol 9, 359-367. 
 
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., 
Yamanaka, S. (2009). Suppression of induced pluripotent stem cell generation by the 
p53-p21 pathway. Nature 460, 1132-1135. 
  
 
149 
 
Hsiung, D.T., Marsit, C.J., Houseman, E.A., Eddy, K., Furniss, C.S., McClean, M.D., 
Kelsey, K.T. (2007). Global DNA methylation level in whole blood as a biomarker in 
head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 16, 108-
114. 
 
Huang, P., He, Z., Ji, S., Sun, H., Xiang, D., Liu, C., Hu, Y., Wang, X., Hui, L. (2011). 
Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. 
Nature 475, 386-389. 
 
Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.E., and 
Melton, D.A. (2008a). Induction of pluripotent stem cells by defined factors is greatly 
improved by small-molecule compounds. Nat Biotechnol 26, 795-797. 
 
Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, 
W., and Melton, D.A. (2008b). Induction of pluripotent stem cells from primary human 
fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26, 1269-1275. 
 
Ichida, J.K., Blanchard, J., Lam, K., Son, E.Y., Chung, J.E., Egli, D., Loh, K.M., Carter, 
A.C., Di Giorgio, F.P., Koszka, K., et al. (2009). A small-molecule inhibitor of tgf-Beta 
signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 5, 491-503. 
 
Ieda, M., Fu, J.D., Delgado-Olguin, P., Vedantham, V., Hayashi, Y., Bruneau, B.G., 
Srivastava, D. (2010). Direct reprogramming of fibroblasts into functional 
cardiomyocytes by defined factors. Cell 142, 375-386. 
 
Issa JP. (2000). The epigenetics of colorectal cancer. Ann N Y Acad Sci 910, 140-153. 
 
Jackson-Grusby, L., Beard, C., Possemato, R., Tudor, M., Fambrough, D., Csankovszki, 
G., Dausman, J., Lee, P., Wilson, C., Lander, E., et al. (2001). Loss of genomic 
methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet 27, 
31-39. 
 
Jones, P.A., Baylin, S.B. (2002). The fundamental role of epigenetic events in cancer. 
Nat Rev Genet 3, 415-428. 
 
Kawamura, T., Suzuki, J., Wang, Y.V., Menendez, S., Morera, L.B., Raya, A., Wahl, 
G.M., Izpisúa Belmonte, J.C. (2009). Linking the p53 tumour suppressor pathway to 
somatic cell reprogramming. Nature 460, 1140-1144. 
 
Khwaja, A., Rodriguez-Viciana, P., Wennström, S., Warne, P.H., Downward, J. (1997). 
Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase 
and protein kinase B/Akt cellular survival pathway. EMBO J 16, 2783-2793. 
  
 
150 
 
Lefort, K., Mandinova, A., Ostano, P., Kolev, V., Calpini, V., Kolfschoten, I., Devgan, 
V., Lieb, J., Raffoul, W., Hohl, D., Neel, V., Garlick, J., Chiorino, G., Dotto, G.P. 
(2007). Notch1 is a p53 target gene involved in human keratinocyte tumor suppression 
through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev 21, 562-
577. 
 
Leong, K.G., Karsan, A. (2006). Recent insights into the role of Notch signaling in 
tumorigenesis. Blood 107, 2223-2233. 
 
 
Li, E., Bestor, T.H., and Jaenisch, R. (1992). Targeted mutation of the DNA 
methyltransferase gene results in embryonic lethality. Cell 69, 915-926. 
 
Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Cañamero, M., Blasco, M.A., 
Serrano M. (2009). The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 
460, 1136-1139. 
 
Li, J., Greco, V., Guasch, G., Fuchs, E., Mombaerts, P. (2007). Mice cloned from skin 
cells. Proc Natl Acad Sci. 104, 2738-2743. 
Li, W., Wei, W., Zhu, S., Zhu, J., Shi, Y., Lin, T., Hao, E., Hayek, A., Deng, H., and 
Ding, S. (2009). Generation of rat and human induced pluripotent stem cells by 
combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4, 16-19. 
 
Lin, A., Karin, M. (2003). NF-kappaB in cancer: a marked target. Semin Cancer Biol 13, 
107-114. 
 
Lin, T., Ambasudhan, R., Yuan, X., Li, W., Hilcove, S., Abujarour, R., Lin, X., Hahm, 
H.S., Hao, E., Hayek, A., et al. (2009). A chemical platform for improved induction of 
human iPSCs. Nat Methods 6, 805-808. 
 
Lo Muzio, L., Pannone, G., Staibano, S., Mignogna, M.D., Grieco, M., Ramires, P., 
Romito, A.M., De Rosa, G., Piattelli, A. (2002). WNT-1 expression in basal cell 
carcinoma of head and neck. An immunohistochemical and confocal study with regard 
to the intracellular distribution of beta-catenin. Anticancer Res 22, 565-576. 
 
Lübbert M. (2000). DNA methylation inhibitors in the treatment of leukemias, 
myelodysplastic syndromes and hemoglobinopathies: clinical results and possible 
mechanisms of action. Curr Top Microbiol Immunol 249, 135-164. 
 
Mandinova, A., Lefort, K., Tommasi di Vignano, A., Stonely, W., Ostano, P., Chiorino, 
G., Iwaki, H., Nakanishi, J., Dotto, G.P. (2008). The FoxO3a gene is a key negative  
 
151 
 
target of canonical Notch signalling in the keratinocyte UVB response. EMBO J 27, 
1243-1254. 
 
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, 
O., Serrano, M., Blasco, M. A. (2009). A p53-mediated DNA damage response limits 
reprogramming to ensure iPS cell genomic integrity. Nature 460, 1149-1153. 
 
Marson, A. et al. (2008). Wnt signaling promotes reprogramming of somatic cells to 
pluripotency. Cell Stem Cell 3, 132-135. 
 
Mikkelsen, T.S., Hanna, J., Zhang, X., Ku, M., Wernig, M., Schorderet, P., Bernstein, 
B.E., Jaenisch, R., Lander, E.S., Meissner, A. (2008). Dissecting direct reprogramming 
through integrative genomic analysis. Nature 454, 49-55. 
 
Moore, L.E., Pfeiffer, R.M., Poscablo, C., Real, F.X., Kogevinas, M., Silverman, D., 
Garcí a-Closas, R., Chanock, S., Tardón, A., Serra, C., Carrato, A., Dosemeci, M., 
Garcí a-Closas, M., Esteller, M., Fraga, M., Rothman, N., Malats, N. (2008). Genomic 
DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish 
Bladder Cancer Study: a case-control study. Lancet Oncol 9, 359-366. 
 
Ogawa, K., Nishinakamura, R., Iwamatsu, Y., Shimosato, D., Niwa, H. (2006). 
Synergistic action of Wnt and LIF in maintaining pluripotency of mouse ES cells. 
Biochem Biophys Res Commun 343, 159-166. 
 
Ohm, J.E., McGarvey, K.M., Yu, X., Cheng, L., Schuebel, K.E., Cope, L., Mohammad, 
H.P., Chen, W., Daniel, V.C., Yu, W., Berman, D.M., Jenuwein, T., Pruitt, K., Sharkis, 
S.J., Watkins, D.N., Herman, J.G., Baylin, S.B. (2007). A stem cell-like chromatin 
pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable 
silencing. Nat Genet 39, 237-242. 
 
Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germline-competent 
induced pluripotent stem cells. Nature 448, 313-317. 
 
Okuyama R, LeFort K, Dotto GP. (2004). A dynamic model of keratinocyte stem cell 
renewal and differentiation: role of the p21WAF1/Cip1 and Notch1 signaling pathways. 
J Investig Dermatol Symp Proc 9, 248-252. 
 
Oswald, F., Liptay, S., Adler, G., Schmid, R.M. (1998). NF-kappaB2 is a putative target 
gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 18, 2077-2088. 
 
Pawlak, M., Jaenisch, R. (2011). De novo DNA methylation by Dnmt3a and Dnmt3b is 
dispensable for nuclear reprogramming of somatic cells to a pluripotent state.Genes Dev. 
25, 1035-1040. 
  
 
152 
 
Pear, W.S., Aster, J.C., Scott, M.L., Hasserjian, R.P., Soffer, B., Sklar, J., Baltimore, D. 
(1996). Exclusive development of T cell neoplasms in mice transplanted with bone 
marrow expressing activated Notch alleles. J Exp Med 183, 2283-2291. 
 
Polo, J.M., Anderssen, E., Walsh, R.M., Schwarz, B.A., Nefzger, C.M., Lim, S.M., 
Borkent, M., Apostolou, E., Alaei, S., Cloutier, J., Bar-Nur, O., Cheloufi, S., Stadtfeld, 
M., Figueroa, M.E., Robinton, D., Natesan, S., Melnick, A., Zhu, J., Ramaswamy, S., 
Hochedlinger, K. (2012). A molecular Roadmap of reprogramming somatic cells into 
iPS cells. Cell 151, 1617-1632.  
 
Pui, J.C., Allman, D., Xu, L., DeRocco, S., Karnell, F.G., Bakkour, S., Lee, J.Y., 
Kadesch, T., Hardy, R.R., Aster, J.C., Pear, W.S. (1999). Notch1 expression in early 
lymphopoiesis influences B versus T lineage determination. Immunity 11, 299-308. 
 
Radtke, F., Wilson, A., Stark, G., Bauer, M., van Meerwijk, J., MacDonald, H.R., Aguet, 
M. (1999). Deficient T cell fate specification in mice with an induced inactivation of 
Notch1. Immunity 10, 547-558. 
 
Ranganathan, P., Weaver, K.L., Capobianco, A.J. (2011). Notch signalling in solid 
tumours: a little bit of everything but not all the time. Nat Rev Cancer 11, 338-351. 
 
Rangarajan, A., Syal, R., Selvarajah, S., Chakrabarti, O., Sarin, A., Krishna, S. (2001). 
Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation 
and generates resistance to apoptosis on matrix withdrawal through PKB/Akt. Virology 
286, 23-30. 
 
Reynolds, T.C., Smith, S.D., Sklar, J. (1987). Analysis of DNA surrounding the 
breakpoints of chromosomal translocations involving the beta T cell receptor gene in 
human lymphoblastic neoplasms. Cell 50, 107-117. 
 
Reznikoff, C.A., Brankow, D.W., Heidelberger, C. (1973). Establishment and 
characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence 
inhibition of division. Cancer Res 33, 3231-3238. 
 
Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., Brivanlou, A.H. (2004). 
Maintenance of pluripotency in human and mouse embryonic stem cells through 
activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10, 
55-63. 
 
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., 
Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B.E., Bergman, Y., Simon, I., Cedar, 
H. (2007). Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for 
de novo methylation in cancer. Nat Genet. 39, 232-236. 
  
 
153 
 
Sekiya, S., Suzuki, A. (2011). Direct conversion of mouse fibroblasts to hepatocyte-like 
cells by defined factors. Nature 475, 390-393 
 
Shi, Y., Do, J.T., Desponts, C., Hahm, H.S., Schöler, H.R., Ding, S. (2008). A combined 
chemical and genetic approach for the generation of induced pluripotent stem cells. 
 Cell Stem Cell 2, 525-528. 
 
Singla, D.K., Schneider, D.J., LeWinter, M.M., Sobel, B.E. (2006). wnt3a but not wnt11 
supports self-renewal of embryonic stem cells. Biochem Biophys Res Commun 345, 
789-795. 
 
Son, E.Y., Ichida, J.K., Wainger, B.J., Toma, J.S., Rafuse, V.F., Woolf, C.J., Eggan, K. 
(2011). Conversion of mouse and human fibroblasts into functional spinal motor 
neurons. Cell Stem Cell 9, 205-218. 
 
Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G., and Hochedlinger, K. (2008). Induced 
pluripotent stem cells generated without viral integration. Science 322, 945-949. 
 
Takahashi, K. & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676. 
 
Taylor, S.M., Jones, P.A. (1979). Multiple new phenotypes induced in 10T1/2 and 3T3 
cells treated with 5-azacytidine. Cell 17, 771-779. 
 
Thélu, J., Rossio, P., Favier, B. (2002). Notch signalling is linked to epidermal cell 
differentiation level in basal cell carcinoma, psoriasis and wound healing. BMC 
Dermatol 2, 7. 
 
Utikal, J., Polo, J.M., Stadtfeld, M., Maherali, N., Kulalert, W., Walsh, R.M., Khalil, A., 
Rheinwald, J.G., Hochedlinger, K. (2009). Immortalization eliminates a roadblock 
during cellular reprogramming in to iPS cells. Nature 460, 1145-1148. 
Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Südhof, T.C., Wernig, M. 
(2010). Direct conversion of fibroblasts to functional neurons by defined factors. Nature 
463, 1035-1041. 
Warren, L., Manos, P.D., Ahfeldt, T., Loh, Y.H., Li, H., Lau, F., Ebina, W., Mandal, 
P.K., Smith, Z.D., Meissner, A., et al. (2010). Highly efficient reprogramming to 
pluripotency and directed differentiation of human cells with synthetic modified mRNA. 
Cell Stem Cell 7, 618-630. 
 
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., 
Weisenberger, D.J., Campan, M., Young, J., Jacobs, I., Laird, P.W. (2007). Epigenetic 
stem cell signature in cancer. Nat Genet 39, 157-158.  
 
154 
 
Wilson, A.S., Power, B.E., Molloy, P.L. (2007). DNA hypomethylation and human 
diseases. Biochim Biophys Acta 1775, 138-162. 
 
Xu, Y., Shi, Y., Ding, S. (2008). A chemical approach to stem-cell biology and 
regenerative medicine. Nature 453, 338-344. 
 
Yuan X, Wan H, Zhao X, Zhu S, Zhou Q, Ding S. (2011). Combined chemical treatment 
enables Oct4-induced reprogramming from mouse embryonic fibroblasts. Stem Cells 29, 
549-553. 
 
 
 